SEMIANNUAL FINANCIAL REPORT OF THE DIASORIN GROUP AT JUNE 30, 2013

Diasorin S.p.A.
Via Crescentino (no building No.) - 13040 Saluggia (VC)
Tax I. D. and Vercelli Company Register n. 13144290155

CONTENTS

BOARD OF DIRECTORS, BOARD OF STATUTORY AUDITORS AND INDEPENDENT AUDITORS. 3

THE DIASORIN GROUP 4

STRUCTURE OF THE DIASORIN GROUP AT JUNE 30, 2013 6

CONSOLIDATED FINANCIAL HIGHLIGHTS 7

INTERIM REPORT ON OPERATIONS 8

REVIEW OF THE GROUP'S OPERATING PERFORMANCE AND FINANCIAL POSITION 11

OPERATING PERFORMANCE IN THE SECOND QUARTER OF 2013 11
OPERATING PERFORMANCE IN THE FIRST HALF OF 2013 18
STATEMENT OF FINANCIAL POSITION OF THE GROUP AT JUNE 30, 2013 25
ANALYSIS OF CONSOLIDATED CASH FLOWS 27
OTHER INFORMATION 28

TRANSACTIONS WITH RELATED PARTIES 28

SIGNIFICANT EVENTS OCCURRING AFTER JUNE 30, 2013 AND BUSINESS OUTLOOK 29

CONDENSED SEMIANNUAL CONSOLIDATED FINANCIAL STATEMENTS AT JUNE 30, 2013 30

CONSOLIDATED INCOME STATEMENT 31

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 32
CONSOLIDATED STATEMENT OF FINANCIAL POSITION 33
CONSOLIDATED STATEMENT OF CASH FLOWS 35
STATEMENT OF CHANGES IN CONSOLIDATED SHAREHOLDERS' EQUITY 36

NOTES TO THE CONDENSED SEMIANNUAL CONSOLIDATED FINANCIAL STATEMENT AT JUNE 30, 2013 AND JUNE 30, 2012 37

CERTIFICATION OF THE CONDENSED SEMIANNUAL CONSOLIDATED FINANCIAL STATEMENTS PURSUANT TO ARTICLE 81-TER OF CONSOB REGULATION NO. 11971 OF MAY 14, 1999, AS AMENDED 59

BOARD OF DIRECTORS, BOARD OF STATUTORY AUDITORS AND INDEPENDENT AUDITORS.

Board of Directors (elected on April 22, 2013)

Chairman	Gustavo Denegri
Deputy Chairman	Michele Denegri
Chief Executive Officer	Carlo Rosa (1)
Directors	Antonio Boniolo Chen Menachem Even Enrico Mario Amo Gian Alberto Saporiti Giuseppe Alessandria (2) (3) Franco Moscetti (2) Maria Paola Landini (2) Roberta Somati (2) Eva Desana Ezio Garibaldi

Board of Statutory Auditors

Chairman	Roberto Bracchetti
Statutory Auditors	Andrea Caretti Ottavia Alfano
Alternates	Bruno Marchina Maria Carla Bottini

Independent Auditors Deloitte & Touche S.p.A.

COMMITTEES

Internal Control and Risks Committee	Franco Moscetti (Chairman) Enrico Mario Amo Roberta Somati
Compensation Committee	Giuseppe Alessandria (Chairman) Roberta Somati Michele Denegri
Nominating Committee	Franco Moscetti (Chairman) Giuseppe Alessandria Michele Denegri
Related-party Committee	Franco Moscetti (Coordinator) Giuseppe Alessandria Roberta Somati

(1) General Manager
(2) Independent Director
(3) Lead Independent Director

THE DIASORIN GROUP

Diasorin is an Italian company listed on the stock market in the **FTSE MIB Index**. It is a global leader in the field of biotechnologies: for over 40 years the company has been developing, producing and commercializing reagent kits for the in vitro diagnostics worldwide.

Diasorin's products are specifically designed for hospital and private testing laboratories, in the market of:

- **immunodiagnostics**
- **molecular diagnostics**

where the Group provides diagnostic tests **in different clinical areas.** Diasorin can offer to the market an assay menu that is unique for its width and presence of specialty tests, which identify Diasorin as the in vitro "**Specialist".**

Over the last 10 years, the Group strengthened its commercial **presence on a global scale**. Starting from the historical reference markets, Europe and USA, the company opened new commercial branches in all the emerging markets, such as Brazil, Mexico, China and Australia, confirming its presence, as **Global Player,** in **over 60 countries**.

Research and Development is pivotal in Diasorin business model. Through its research activity and the following expansion of its **immunodiagnostic** and, more recently, **molecular diagnostic** products, the Group constantly supports clinical laboratory needs and activities, providing solutions that are:

- innovative;
- fully automated and standardized;
- reliable;
- easy to use;
- affordable.

The fruits of its current success and its future growth lie in the Group's dedication to constantly improve the quality of its products and develop menus addressed to laboratories.

Diasorin internally manages the primary processes involved in the research, production, and distribution aspects, that is, the process that, starting with the development of new products, leads to the marketing of those products.

The Group's manufacturing organization consists of several facilities located in Europe, USA and Africa.

Saluggia	Italy	At the Group's Parent Company's headquarters
Stillwater	USA	At the headquarters of Diasorin Inc.
Dietzenbach	Germany	At the headquarters of Diasorin Deutschland GmbH
Dublin	Ireland	At the headquarters of Diasorin Ireland Ltd
Dartford	UK	At the headquarters of Diasorin S.p.A-UK Branch
Kyalami	South Africa	At the headquarters of Diasorin South Africa (Pty) Ltd

The Group headed by Diasorin S.p.A. is comprised of **24 companies** and **5 branches** on **5 continents**.

In Europe, United States, Mexico, Brazil, China, Australia and Israel, the Diasorin Group sells its products mainly through its marketing companies that are part of the Diasorin Group.
In countries where the Group does not have a direct presence, it operates through an international network of more than 80 independent distributors

STRUCTURE OF THE DIASORIN GROUP AT JUNE 30, 2013



CONSOLIDATED FINANCIAL HIGHLIGHTS

Income statement *(in thousands of euros)*	**2nd quarter 2013(*)**	**2nd quarter 2012(*)**	**1st half 2013**	**1st half 2012**
Net revenues	113,880	115,033	219,719	220,686
Gross profit	79,843	78,546	151,891	153,281
EBITDA (1)	42,293	44,738	83,873	88,886
EBIT	35,401	37,576	69,583	74,746
Net profit for the period	20,515	23,085	41,041	45,539

Statement of financial position *(in thousands of euros)*	**06/30/2013**	**12/31/2012(**)**
Capital invested in non-current assets	209,843	212,992
Net invested capital	322,847	317,834
Net financial position	56,750	47,168
Shareholders' equity	379,597	365,002

Statement of cash flows *(in thousands of euros)*	**2nd quarter 2013(*)**	**2nd quarter 2012(*)**	**1st half 2013**	**1st half 2012**
Net cash flow for the period	(17,904)	(10,789)	(37,093)	5,698
Free cash flow (2)	12,046	26,251	37,395	42,732
Capital expenditures	7,581	7,780	14,330	14,588
Number of employees			1,610	1,569

(*) Unaudited data.
(**)Following the retrospective application of the amendment to IAS 19 from January 1, 2013 the comparative figures at January 1 and December 31, 2012 have been restated as required by IAS 1. See section "New accounting principles" of the Report on operations for additional information.

(1) The Board of Directors defines EBITDA as the "operating result (EBIT)" before amortization of intangibles and depreciation of property, plant and equipment.

(2) Free cash flow is the cash flow from operating activities, counting utilizations for capital expenditures but before interest payments and acquisitions of companies and business operations.

INTERIM REPORT ON OPERATIONS

Foreword

These condensed semiannual consolidated financial statements were prepared in accordance with international accounting principles (International Accounting Standards – IAS and International Financial Reporting Standards – IFRS) and the corresponding interpretations (Standing Interpretations Committee – SIC and International Financial Reporting Interpretations Committee – IFRIC) published by the International Accounting Standards Boards (IASB). More specifically, it is being presented in condensed form, in accordance with the international accounting principle that governs interim financial reporting (IAS 34), as adopted by the European Union, and complies with the requirements of Article 154-*ter,* Sections 2 and 3, of Legislative Decree No. 58 of February 24, 1998.

The accounting principles applied to prepare this consolidated semiannual report are consistent with those used for the annual consolidated financial statements at December 31, 2012, except as otherwise stated under " New Accounting principles", in the Notes to the Semiannual Consolidated Financial Statements.

Following application of the amendment to IAS 19 (retrospectively) from January 1, 2013 figures previously reported in the statement of financial position at December 31, 2012 and the statement of comprehensive income for the first half of 2012, have been restated in accordance with the requirements of IAS 1. For further details, refer to " New accounting principles" in the Notes to the Semiannual Consolidated Financial Statements.

Key events in the first half of 2013

In the first half of 2013, the Group launched the Clostridium Difficile GDH assay on its Liaison analyzers family.
The addition of the C. Difficile GDH assay to the Diasorin menu, already including Clostridium Difficile Toxin A&B and Helicobacter Pylori, allows Diasorin customers to optimize this screening test with a unique automated solution.

In the second quarter of 2013, Diasorin signed a 4-year agreement with Seegene, a global leader of multiplex molecular diagnostics.
Under the OEM agreement, Diasorin manufactures and supplies nucleic acid extraction instruments and kits to Seegene under the Seeprep® 12 brand name.
The Seeprep® 12 instrument is based on Diasorin's own compact bench top nucleic extraction system. Seegene will provide the Seeprep® 12 instrument and Seeprep® extraction kits, also manufactured by Diasorin, together with its own nucleic acid amplification systems and kits.

In the same quarter of 2013, Diasorin strengthened its menu offer in the US market with the approval by the Food and Drug Administration to market the Aldosterone assay on the LIAISON family in the US.
The addition of the new Aldosterone assay to the Liaison analyzer menu and its combination with the Direct Renin assay, positions Diasorin as the only player in the hypertension market, able to provide its customers (hospitals, laboratories) with the opportunity to complete the "Hypertension panel", and consolidate the broadest Bone & Mineral and Endocrinology menus on a single fully automated system, with unique assays and recognized high quality.

In June, Diasorin announced the launch of a new molecular diagnostic test for the detection of Parvovirus B19 and plasma and serum sample, available outside USA and Canada only. The new IAM PARVO is the third test used on LIAISON®, together with the first two assay, IAM BKV and IAM VZV, already launched at the end of 2012. The new molecular diagnostic test is of primary importance because, while the serological test in immunodiagnostic are normally used for the initial diagnosis in immunocompetent individuals, that is having an healthy immune system, the molecular tests are needed for immunocompromised patients and are recommended to confirm IgM anti-Parvovirus positive results.

In addition, in the first half of 2013, Diasorin launched the new Chlamydia Trachomatis IgG and IgA assays on LIAISON analyzer family, available outside US and Canada, providing the first fully automated CLIA tests to be used in the determination of serological of the Chlamydia Trachomatis infectious disease. The new Chlamydia Trachomatis IgG and IgA assays on LIAISON platforms are intended to aid in the determination of antibodies to Chlamydia Trachomatis in human serum or plasma, representing both a more accurate, practical and faster solution than the one on ELISA technology and a more economical solution for laboratories using more expensive technologies, such as molecular diagnostics. Moreover the new Chlamydia Trachomatis IgG and IgA assays satisfy customers' needs like standardization among laboratories, easy to use, rapid and accurate identification of active infection, and assessment of past infection as possible cause of infertility and reactivation.

The foreign exchange market

In the foreign exchange market, the average exchange rate of the euro versus the U.S. dollar was up 1.3% in the first half of 2013, compared with the same period last year. The exchange rate at June 30, 2013 was 1.3080 U.S. dollars for one euro, compared with 1.3194 U.S. dollars for one euro at the end of 2012 (-0.9%). The euro appreciated in value also vis-à-vis the other currencies used by the Group, with the exchange rate up compared with the first six months of 2012, particularly for the South African rand (+17.7%), the Brazilian real (+10.5%) and the Australian dollar (+3.2%).

In the second quarter of 2013, the average exchange rate of the euro versus the U.S. dollar was up 1.9% compared with the same period last year. The euro appreciated in value also vis-à-vis the other currencies used by the Group, with the exchange rate up compared with the second quarter of 2012, particularly for the South African rand (+19%), the Brazilian real (+7.3%) and the Australian dollar (+4%).

The exchange rates impacted significantly on the Group's operating performance of the period.

The table below provides a comparison of the exchange rates for the first half of 2013 and 2012 (source: Italian Foreign Exchange Bureau):

Currency	Average rates for				Rates at	
	1st half 2013	1st half 2012	2nd quarter 2013	2nd quarter 2012	6/30/2013	6/30/2012
U.S. dollar	1.3134	1.2965	1.3062	1.2814	1.3080	1.2590
Brazilian real	2.6683	2.4144	2.6994	2.5167	2.8899	2.5788
British pound	0.8508	0.8225	0.8506	0.8100	0.8572	0.8068
Swedish kronor	8.5311	8.8824	8.5652	8.9133	8.7773	8.7728
Czech koruna	25.6994	25.1742	25.8313	25.2693	25.9490	25.6400
Canadian dollar	1.3341	1.3040	1.3368	1.2949	1.3714	1.2871
Mexican peso	16.4982	17.1867	16.2956	17.3620	17.0413	16.8755
Israeli shekel	4.8182	4.9231	4.7407	4.9021	4.7386	4.9453
Chinese Yuan	8.1285	8.1901	8.0376	8.1072	8.0280	8.0011
Australian dollar	1.2961	1.2559	1.3203	1.2699	1.4171	1.2339
South African rand	12.1153	10.2942	12.3996	10.4214	13.0704	10.3669

REVIEW OF THE GROUP'S OPERATING PERFORMANCE AND FINANCIAL POSITION

OPERATING PERFORMANCE IN THE SECOND QUARTER OF 2013

In the second quarter of 2013, the Diasorin Group's revenues totaled 113,880 thousand euros, in line with 2012 revenues at constant exchange rate (-1% at current exchange rate), up by 7.6% compared with the first quarter of 2013. The Group achieved this result despite the difficult macroeconomic environment in Europe, where the contraction in the IVD market continues (Italy -3.4%, France -2.5% and Spain -4.2%).

In detail:

i) 11.2% growth at constant exchange rate (+10.7% at current exchange rate), compared with the same period last year, of CLIA technology product line, net of Vitamin D, driven by the expansion of LIAISON XL installed base and products launched on the market in the past quarters.

ii) The decline in Vitamin D sales (-9.5% at constant exchange rate), with different trends depending on the geographical areas. Europe recorded a steady growth among under penetrated countries, such as Italy and Germany; emerging countries, mainly Brazil and Australia, reported growing revenues. In the North American market, even though still in downtrend, the negative impact deriving from price renegotiation over the last months was mitigated

iii) The expansion of LIAISON XL and LIAISON installed base: 137 LIAISON XL and 49 LIAISON have been placed, with 5,060 units installed in the second quarter of 2013.

As a result of the above, net of Vitamin D, the Group's revenues increased by 4.6% at constant exchange rate (+3.7% at current exchange rate) compared with the same period in 2012.

Molecular business sales were obtained mainly from customers acquired with business in 2012 (equipment totaled 20% of revenues).

In the second quarter of 2013, the gross profit amounted to 79,843 thousand euros, up by +1.7% or 1,297 thousand euros compared with 78,546 thousand euros in the same period. The ratio of gross profit to revenues increased from 68.3 percentage points to 70.1 percentage points.

Operating expenses of the period totaled 41,326 thousand euros, up by 5.3 percentage points or 2,075 thousand euros compared with the same period in 2012 and were mainly related to costs incurred to support the Molecular business launch.

Other operating expenses equal to 3,166 thousand euros, increased by 1,397 thousand euros compared with the second quarter of 2012. This item reflects the exchange rate fluctuation: the amount includes a negative translation difference of 1,870 thousand euros related to commercial items (544 thousand euros in the same period of 2012).

EBITDA, impacted by the abovementioned currency effect, amounted to 42,293 thousand euros (44,738 thousand euros in 2012), equal to 37.1% of revenues and down by 1.8 percentage points compared with 2012. Excluding the molecular business contribution in the periods under comparison, EBITDA would be equal to 39 percentage points of revenues (about 40% in 2012): at constant exchange rate, the EBITDA margin of the periods under comparison is in line.

In the second quarter 2013, consolidated EBIT decreased from 37,576 thousand euros in 2012 to 35,401 thousand euros in the second quarter of 2013, equal to 31.1% of revenues, down by 1.6% percentage points compared with the same period in 2012.

In the second quarter of 2013, net financial expense totaled 1,817 thousand euro, compared with net financial expense of 1,633 thousand euros in the same period in 2012.

Income taxes totaled 13,069 thousand euros in the second quarter of 2013 (12,858 thousand euros in the same period last year). The tax rate increased from 35.8% in the second quarter of 2012 to 38.9% in the second quarter of 2013, due mainly to the different periods of the dividend payment related to nondeductible tax withholdings from subsidiaries.

Finally, in the second quarter of 2013 the net profit totaled 20,515 thousand euros, down by 11.1% compared with the same period in 2012.

The table that follows shows the consolidated income statement for the quarters ended June 30, 2013 and June 30, 2012:

CONSOLIDATED INCOME STATEMENT

(in thousands of euros)	**2nd quarter 2013(*)**	**as a% of revenues**	**2nd quarter 2012(*)**	**as a% of revenues**
Sales and service revenues	113,880	100.0%	115,033	100.0%
Cost of sales	(34,037)	29.9%	(36,487)	31.7%
Gross profit	**79,843**	**70.1%**	**78,546**	**68.3%**
Sales and marketing expenses	(22,450)	19.7%	(20,512)	17.8%
Research and development costs	(6,177)	5.4%	(6,282)	5.5%
General and administrative expenses	(12,699)	11.2%	(12,457)	10.8%
Total operating expenses	**(41,326)**	**36.3%**	**(39,251)**	**34.1%**
Other operating income (expense)	(3,116)	2.7%	(1,719)	1.5%
Non-recurring amount	-	-	*(853)*	*0.7%*
EBIT	**35,401**	**31.1%**	**37,576**	**32.7%**
Net financial income (expense)	(1,817)	1.6%	(1,633)	1.4%
Profit before taxes	**33,584**	**29.5%**	**35,943**	**31.2%**
Income taxes	(13,069)	11.5%	(12,858)	11.2%
Net profit	**20,515**	**18.0%**	**23,085**	**20.1%**
EBITDA (1)	**42,293**	**37.1%**	**44,738**	**38.9%**

(*) Unaudited data.

(1) The Company defines EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

Net Revenues

As mentioned earlier in this report, in the second quarter of 2013, revenues totaled 113,880 thousand euros, with a slight contraction (-1%) at current exchange rate and in line at constant exchange rate compared with the same period last year.

Breakdown of revenues by geographic region

The table below provides a breakdown of the consolidated revenues of the Diasorin Group by geographic region of destination.

(in thousands of euros)	**2nd quarter 2013**	**2nd quarter 2012**	**% Change at current exchange rates**	**% Change at constant exchange rates**
Europe and Africa	54,473	52,176	4.4%	4.4%
North America	27,563	32,413	-15.0%	-13.4%
Asia Pacific	18,598	18,474	0.7%	1.4%
Central and South America	13,246	11,970	10.7%	15.5%
Total	**113,880**	**115,033**	**-1.0%**	**0.0%**



Europa e Africa

Revenues booked in Europe and Africa totaled 54,473 thousand euros, up by 4.4% compared with the same period last year (52,176 thousand euros). Specifically, net of revenues generated from Vitamin D sales, all countries grow apace, with the only exception of France and Israel with a result in line with 2012. CLIA reagent sales, net of Vitamin D, increased by 12%, compared with the same period last year.

Despite a contraction of 3.4% in the reference market, higher contribution to revenue was provided by Germany (+15.4%) and Italy (5.8%). Moreover a decrease in sale on the French market (-9.5%), due mainly to the decline in Vitamin D sales, was partly offset by CLIA products, up by 11 percentage points compared with 2012.

North America

In the second quarter of 2013, the North America sales region reported revenues of 27,563 thousand euros, down by 13.4% at constant exchange rate (15% at current exchange rate) compared with the same period last year, but up by 4 percentage points, compared with the first quarter of 2013.

As in previous quarters, North America performance was mainly impacted by lower Vitamin D sales (-15.9% at constant exchange rate, -17.4% at current exchange rate), even if at a slower pace than in

the first quarter of 2013, resulting from a slowdown in price reduction granted to the Group's customers. On the contrary, revenues of CLIA specialties, increased by 20.4 percentage points at constant exchange rate (+18.2% at current exchange rate).

Asia Pacific

In the second quarter of 2013, the Asia Pacific sales region reported a slight increase in revenues, equal to 18,598 thousand euros (+1.4% at constant exchange rate or +0.7% at current exchange rate). Countries like China and Australia, where the Group has its own sales network, reported a high growth.
Sales of all CLIA products grew by 15.5% (16.5 percentage points at current exchange rate) in the Chinese market; in Australia, sales increased by 37.3% at constant exchange rate (+31.6% at current exchange rate) due to the good performance of both Vitamin D and CLIA products (sales almost doubled compared with 2012).
Sales decreased by -18.9% in the markets served through Group distributors, resulting from the different seasonality of purchases made by large distributors.

Central and South America

The Latin American sales region reported revenues of 13,246 thousand euros in the second quarter of 2013, up 10.7 percentage points compared with 11,970 thousand euros in the second quarter of 2012. Net of the exchange rates impact, the percentage point increase amounted to 15.5.
This change is mainly attributable to the performance of the Brazilian subsidiary, up by 22% at constant exchange rates and +13.4% at current exchange rates, resulting from the increase in Vitamin D and instruments sales. Rising sales were recorded also in countries where the Group operates through local distributors (+8.4% compared with the same period last year), due mainly to reagents sale (+16.0% compared with 2012) fostered by the high number of instruments placements in the past quarters. In the second quarter of 2013, net of the currency effect, the sales of the Mexican subsidiary decreased by 4.5 percentage points (+1.4% at current exchange rate), compared with the second quarter of 2012.

Breakdown of revenues by technology

The tables that follow show the percentage of the Group's consolidated revenues contributed by each technology in the second quarter of 2013 and 2012.

% of revenues contributed	**2nd quarter 2013**	**2nd quarter 2012**
RIA	3.1%	3.5%
ELISA	15.1%	17.2%
CLIA	67.8%	66.9%
MOLECULAR	0.8%	0.4%
Instruments sales and other revenues	13.2%	12.0%
Total	**100.0%**	**100.0%**



In the second quarter of 2013, the percentage of total revenues provided by CLIA products increased, due to the abovementioned rising sales of LIAISON reagents, completely offsetting the decline in Vitamin D. The data in the table reflect the steady physiological decline of the contribution provided by the RIA and ELISA technologies (which are more dated and function on open systems). Revenues generated by equipment sale grew by 11.5% at constant exchange rate (+9.7% at current exchange rate), producing an increase of almost 1 percentage points, compared with the second quarter of 2012.

At June 30, 2013, a total of about 5,060 LIAISON automated analyzers were installed at facilities operated by direct and indirect Group customer, for an increase of 186 units compared with the installed base at March 31, 2012.

Operating performance

The evaluation of the Group's operating performance in the second quarter 2013 is in line with the expectations and trend recorded in the last quarters, though euro appreciation in value vis-à-vis with the other currencies used by the Group influenced Diasorin's operating performance.

In the second quarter of 2013, the gross profit amounted to 79,843 thousand euros, up by +1.7% compared with 78,546 thousand euros in the same period. The ratio of gross profit to revenues increased from 68.3 percentage points to 70.1 percentage points.

This trend resulted from: *i.* the different geographic sales mix of the periods under comparison, with higher profit in countries where the Group has a direct presence; *ii.* Lower cost of sales, due to reduced royalty expense on some license agreement expired in 2012.

In the second quarter of 2013, operating expenses totaled 41,326 thousand euros, up by 5.3 percentage points compared with the same period in 2012. The ratio of operating expenses to total revenues increased from 34.1% to 36.3%, as a result of the Molecular diagnostics business in start up phase. Excluding the Molecular business, the ratio to revenues would be equal to 34.8%.

Research and development costs totaled 6,177 thousand euros, in line with 2012 results (6,282 thousand euros in the second quarter of 2012) and refer to activities concerning the development of molecular diagnostics new products. In the second quarter of 2013, the ratio of research and development costs to revenues amounted to 5.4 percentage points, in line with the second quarter of 2012.

Sales and marketing expenses totaled 22,450 thousand euros, up by 9.4% compared with the second quarter of 2012, due to the costs incurred to support the launch of new molecular products.

General and administrative expenses totaled 12,699 thousand euros, slightly increasing compared with the second quarter of 2012 (+1.9%), their ratio to total revenues equal to 11.2 percentage points (in line with the second quarter of 2012).

Other operating expenses equal to 3,166 thousand euros (1,719 thousand euros in the second quarter of 2012) include a negative translation difference of 1,870 thousand euros related to commercial items (negative translation difference of 544 thousand euros in the same period of 2012), deriving from a sharp depreciation of the Brazilian Real and the Australian dollar (including 1,398 thousand euros for valuation purposes).

EBITDA, impacted by the abovementioned currency effect, amounted to 42,293 thousand euros (44,738 thousand euros in 2012), equal to 37.1% of revenues and down by 1.8 percentage points compared with 2012. Excluding the molecular business contribution in the periods under comparison, EBITDA would be equal to 39 percentage points of revenues (about 40% in 2012): at constant exchange rate, the EBITDA margin of the periods under comparison is in line.

In the second quarter of 2013, consolidated EBIT totaling 35,401 thousand euros, equal to 31.1% of revenues, down by 5.8 percentage points compared with the same period in 2012.

Financial income and expense

In the second quarter of 2013, net financial expense totaled 1,817 thousand euro, compared with net financial expense of 1,633 thousand euros in the same period in 2012.

The fair value of the Group's financial instruments was positive by 312 thousand euros (loss of 623 thousand euros in the second quarter of 2012), recognized purely for valuation purposes without any impact on cash flow for the period.

The currency translation effect on other financial balances, which was negative by 1,131 thousand euros (negative by 270 thousand euros in the second quarter of 2012), related mainly to the Euro exchange rate in the intercompany financing disbursed by the Group's Parent company to the Australian subsidiary in the local currency (708 thousand euros), together with the financial balances of subsidiaries that use currencies different from the Group's Parent Company currency; in

this case as well, translation difference include 709 thousand euros recognized for valuation purposes that have no impact on cash flows.

Interests and other financial expense for the period included 686 thousand euros in factoring transaction fees (599 thousand euros in the second quarter of 2012), due to the increase in receivable assignment transactions executed during the period.

Profit before taxes and net profit

The second quarter of 2013 ended with a result before taxes of 33,584 thousand euros, which generated a tax liability of 13,069 thousand euros, down from the same period last year, when the result before taxes and the corresponding tax liability amounted to 35,943 thousand euros and 12,858 thousand euros, respectively.

The tax rate increased from 35.8% in the second quarter of 2012 to 38.9% in 2013, due mainly to higher amount of non-deductible taxes withheld on dividends the Group's Parent Company received from foreign subsidiaries; in particular, the impact of the taxes amounted to 830 thousand euros in the second quarter of 2013 (137 thousand euros in the second quarter of 2012).

The consolidated net profit for the second quarter of 2013 totaled 20,515 thousand euros (23,085 thousand euros in the same period last year), for a decrease of 11.1%.

OPERATING PERFORMANCE IN THE FIRST HALF OF 2013

In the first half of 2013, the Diasorin Group reported revenues of 219,719 thousand euros, slightly higher at constant exchange rate (+0.7%) compared with the same period last year (220,886 thousand euros) and essentially in line at current exchange rate.

The positive performance of CLIA products continued, net of Vitamin D, up 13.5 percentage points at constant exchange rate (around 13% at current exchange rate), to offset the decline in Vitamin D sales. Noteworthy is the growth in the clinical areas of Tumor markers, Infectious Disease, Prenatal Screening, Parvovirus and the new HIV and Viral Hepatitis assays line. This result was achieved through the introduction of LIAISON XL automated analyzer, that enabled the Group to provide its customers with a solution to compete with the major players in this market segment.

In the first half of 2013, the Molecular business generated revenues of 1,717 thousand euros compared with 480 thousand euros in 2012. These sales were mainly obtained from customers acquired together with NorDiag business operations in 2012. Revenues connected to this technology are expected at the end of 2013, after the launch of the first molecular diagnostic products using LAMP technology, started in the second quarter of 2013.

In the first six months of 2013, Diasorin placed 281 LIAISON XL, bringing the installed base to 886 instruments (including 45 in the validation phase at customers facilities). An additional 39 LIAISON analyzers have been placed, bringing to 320 the total number of analyzers installed in the first half of 2013.

The gross profit totaled 151,891 thousand euros, compared with 153,281 thousand euros in the same period in 2012, for a decrease of 0.9% or 1,390 thousand euros. At June 30, 2013, the ratio of gross profit to revenues was equal to 69.1%, in line with 2012 results.

At June 30, 2013, operating expenses totaled 79,720 thousand euros, up by 4 percentage points or 3,037 thousand euros compared with the same period in 2012, mainly due to the costs to support the Molecular business launch.

At June 30, 2013, EBITDA amounted to 83,873 thousand euros, equal to 38.2% of revenues, compared with 88,886 thousand euros or 40.3% of revenues, in 2012. Excluding the Molecular business, EBITDA would be slightly more than 40 percentage points of revenues, in line with 2012 data.

In the first six months of 2013, consolidated EBIT totaled 69,583 thousand euros, compared with 74,746 in the same period last year, equal to 31.7% of revenues, compared with 33.9% of revenues in 2012.

Net financial expense totaled 2,869 thousand euros in the first half of 2013, compared with net financial expense of 1,645 thousand euros in the same period last year. The difference between these two periods is chiefly the result of the exchange rates fluctuation: the first half of 2013 reported expense of 905 thousand euros related to the translation effect, compared with a gain of 214 thousand euros in the first half of 2012.

As a result of the items discussed above, the cumulative net profit totaled 41,041 thousand euros, down 9.9 percentage points compared with the first half of 2012.

The table that follows shows the consolidated income statement for the quarters ended June 30, 2013 and June 30, 2012:

CONSOLIDATED INCOME STATEMENT

(in thousands of euros)	**1st half 2013**	**as a% of revenues**	**1st half 2012**	**as a% of revenues**
Sales and service revenues	219,719	100.0%	220,686	100.0%
Cost of sales	(67,828)	30.9%	(67,405)	30.5%
Gross profit	**151,891**	**69.1%**	**153,281**	**69.5%**
Sales and marketing expenses	(43,031)	19.6%	(40,617)	18.4%
Research and development costs	(12,187)	5.5%	(11,757)	5.3%
General and administrative expenses	(24,502)	11.2%	(24,309)	11.0%
Total operating expenses	**(79,720)**	**36.3%**	**(76,683)**	**34.7%**
Other operating income (expense)	(2,588)	1.2%	(1,852)	0.8%
non- recurring amount	-	-	*(853)*	*0.4%*
EBIT	**69,583**	**31.7%**	**74,746**	**33.9%**
Net financial income (expense)	(2,869)	1.3%	(1,645)	0.7%
Profit before taxes	**66,714**	**30.4%**	**73,101**	**33.1%**
Income taxes	(25,673)	11.7%	(27,562)	12.5%
Net profit	**41,041**	**18.7%**	**45,539**	**20.6%**
EBITDA (1)	**83,873**	**38.2%**	**88,886**	**40.3%**

(1) The Company defines EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRSs and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

Net Revenues

In the first six months of 2013, revenues totaled 219,719 thousand euros, in line with the previous year (220,686 thousand euros).
Molecular business sales of the period totaled 1,717 thousand euros and were obtained mainly from customers acquired with NorDiag business in 2012.

The evolution of sales was due to the following elements:

i) 13.5% increase at constant exchange rate (12.9% at current exchange rate) in CLIA technology product line, net of Vitamin D, thanks to the LIAISON XL success and new products launched on the market in 2013 (exceeding the target of 100 assays available);

ii) 17.4% ca. increase (at current exchange rate) in instruments and consumables sales, with a positive impact on the future generation of revenues derived from reagent sales;

iii) 12.4 % decrease at constant exchange rate (13.4% at current exchange rate) in Vitamin D sales, compared with 2012, mainly due to the reprogramming of selling price caused by competing products introduced on the market. Worthmentioning is the slowdown in sales, at the end of the first six months of 2013, mainly due to lower price reduction in North America and higher revenues in important markets such as (Italy, Germany, Australia and Brazil);

iv) 7.4% increase at constant exchange rate in Group's sales, net of Vitamin D (6.2% at current exchange rate).

A Breakdown of revenues by geographic region

The table below provides a breakdown by geographic region of destination of the consolidated revenues of the Diasorin Group. The first half 2012 data have been reclassified allocating Murex products sales to the reference regions.

(in thousands of euros)	1st half 2013	1st half 2012	% Change at current exchange rates	% Change at constant exchange rates
Europe and Africa	106,089	102,229	3.8%	3.8%
North America	54,204	65,580	-17.3%	-16.3%
Asia Pacific	34,335	30,684	11.9%	12.6%
Central and South America	25,091	22,193	13.1%	19.9%
Total	**219,719**	**220,686**	**-0.4%**	**0.7%**



Europe and Africa

Despite the difficult macroeconomic environment that characterized most of the European markets in 2012 continued in first months of 2013, revenues recorded in the Europe and Africa sales region totaled 106,089 thousand euros, for a gain of 3.8%. Specifically:

i) revenues growth in the Italian market (+5.7%), despite a contraction of 3.4% in the reference market, driven by the introduction of new products in the Hepatitis and Endocrinology clinical areas, the outstanding performance of Vitamin D sales and the enrichment of the Infectious Diseases panel. This result was achieved through LIAISON XL analyzers installed in 2012 and now fully operational.

ii) Growth in the German market (+13.4%), due to long-terms contracts signed in 2012 with big chains of private laboratories which adopted LIAISON XL and the introduction of new products (Endocrinology).

iii) Sales slowdown in the French market (-5.6%), as a result of Vitamin D performance. Net of sales, the French market reported 6-percentage point growth, despite a 2.5% decrease in the reference market. Sales of CLIA reagents, excluding Vitamin D, were up over 15 percentage points, in the first half of 2013.

iv) Growth of the main countries in the area, excluding UK, Belgium, Spain and Israel that made up for lost ground, net of the decrease in Vitamin D sales.

North America

In the first six months of 2013, the North America sales region reported revenues of 54,204 thousand euros, down by 16.3% compared with the first six months of 2012 (-17.3% at current exchange rates). This change reflects two opposing phenomena:

i) the outstanding performance of CLIA specialties increased by 19.6 precentage points at constant exchange rate (+18.1% at current exchange rate) through Infectiology and Prenatal Screening product families;
ii) the trend on Vitamin D sales (-19.9% at constant exchange rate, -20.9% at current exchange rate) mainly driven by a reduction in sale price. This phenomenon slowed down at the end of the first half 2013, as previously reported.

Asia Pacific

In the first half of 2013, revenues of the Asia Pacific sales region amounted to 34,335 thousand euros, up by 12.6% at constant exchange rate (+11.9% or 3,651 thousand euros at current exchange rate), compared with the same period in 2012. This situation is the net result of the:

i) good performance of the Chinese subsidiary, with revenues increased by 14 percentage points at constant exchange rate (+14.9% at current exchange rate) on all CLIA products. Noteworthy is the success of LIAISON XL automated analyzer, launched in December 2012;

ii) sales growth in the Australian market (+ 46.1% at constant exchange rate, +41.6% at current exchange rate), due to Vitamin D revenues recovery and diversification of catalog, that led to higher revenues related to CLIA products (which almost tripled);

iii) Steady growth of revenues in the markets served through the Group's distributors.

Central and South America

The Latin American sales region reported revenues of 25,091 thousand euros in the first half of 2013, up by 19.9 percentage points (+13.1% at current exchange rates) compared with 22,193 thousand euros in the same period last year. This change is mainly attributable to:

i) the performance of the Brazilian subsidiary (+20.4% at constant exchange rates, +9% at current exchange rates), due mainly to the good performance of Vitamin D and to instruments and consumables sale;

ii) the performance of the network of the Group's distributors, (+25.4% compared with the first half of 2012) in countries where the Group does not have a direct presence. In this area, strong equipment sale recorded in December 2012, are now enjoying routine activity levels, generating a steady and growing revenue stream from the sale of reagents (+22.6%);

iii) a slight decrease in sales of the Mexican subsidiary, net of the currency effect (-0.7% at constant exchange rate, +3.4% at current exchange rate).

Breakdown of revenues by technology

The tables that follow show the percentage of the Group's consolidated revenues contributed by each technology in the first half of 2013 and 2012.

% of revenues contributed	**1st half 2013**	**1st half 2012**
RIA	3.2%	3.8%
ELISA	15.5%	17.5%
CLIA	67.4%	67.4%
MOLECULAR	0.8%	0.2%
Instruments sales and other revenues	13.1%	11.1%
Total	**100.0%**	**100.0%**





In the first half of 2013, the percentage of total revenues provided by CLIA products was in line with 2012 data. Revenues generated by instruments sale +19.8% at constant exchange rate (+17.4% at current exchange rate), producing an increase of 2 percentage points, contrasted the decrease in Vitamin D sale (almost completely offset by growing ex Vitamin D CLIA revenues); instruments sale will have a positive impact on revenues generated by reagents in the next months. The data in the table reflect the steady physiological decline of the contribution provided by the RIA and ELISA technologies.

Operating performance

The evaluation of the Group's operating performance in the second quarter 2013 is in line with the expectations and trend recorded in the last quarters.

The gross profit totaled 151,891 thousand euros, compared with 153,281 thousand euros in the same period in 2012. At June 30, 2013, the ratio of gross profit to revenues was equal to 69.1%, with a slight decline compared with 2012: this change was mainly due to different geographic sales mix (higher instruments sale and lower revenues generated by reagents, compared with the same period in 2012). This phenomenon offset the positive effect derived from reduced royalty expense on some license agreement expired in 2012.
Operating expenses totaled 79,720 thousand euros, up by 4 percentage points compared with the same period in 2012, their ratio to total revenues equal to 36.3%, compared with 34.7% in the first six months of 2012, due mainly to the contribution of the molecular business, in start up phase.

Research and development costs increased by 3.7% compared with the same period last year. This item refers to the development of new molecular diagnostic products. The ratio of research and development costs to revenues was equal to 5.5 percentage points, compared with 5.3 percentage points in the first half of 2012.

General and administrative expenses amounted to 24,502 thousand euros, in line with 2012, equal to 11.2 percentage points of revenue (in line with the first half of 2012).

Other operating expenses equal to 2,588 thousand euros (1,852 thousand euros in the first half of 2012) include a negative translation difference of 600 thousand euros related to commercial items (negative translation difference of 801 thousand euros in the same period of 2012), 423 thousand euros of additions for provisions to risks and allowances for doubtful accounts (2012 reversals amounted to 713 thousand euros) and tax charges of 1,107 thousand euros (386 thousand euros in the first half of 2012).

EBITDA totaled 83,873 thousand euros, down by 5.6 percentage points compared with the same period last year, decreasing from 40.3 percentage points in 2012 to 38.2 in 2013. Excluding the molecular business contribution in the periods under comparison, EBITDA slightly more than 40 percentage points, in line with 2012.

In the first half of 2013, consolidated EBIT amounted to 69,583 thousand euros, equal to 31.7 % of revenues, down by 6.9 percentage points compared with the same period in 2012.

Financial income and expense

In the first half of 2013, net financial expense totaled 2,869 thousand euro, compared with net financial expense of 1,645 thousand euros in the same period in 2012.

The fair value of the Group's financial instruments was negative by 368 thousand euros, compared with 373 thousand euros in the first half of 2012.

The currency translation effect on other financial balances, which was negative by 905 thousand euros (positive by 214 thousand euros in the first half of 2012), related mainly to the Euro exchange rate in the intercompany financing disbursed by the Group's Parent company to the Australian subsidiary in the local currency (538 thousand euros), together with the financial transactions of subsidiaries that use currencies different from that of the Group's Parent Company.

Interests and other financial expense for the period included 1,098 thousand euros in factoring transaction fees, in line with 2012 data.

Profit before taxes and net profit

The first half of 2013 ended with a result before taxes of 66,714 thousand euros, which generated a tax liability of 25,673 thousand euros, down from the same period last year, when the result before taxes and the corresponding tax liability amounted to 73,101 thousand euros and 27,562 thousand euros, respectively.

The tax rate increased from 37.7% in the first half of 2012 to 38.5% in the first six months of 2013.

The consolidated net profit for the first six months of 2013 totaled 41,041 thousand euros (45,539 thousand euros in the same period last year), for a decrease of 9.9%.

STATEMENT OF FINANCIAL POSITION OF THE GROUP AT JUNE 30, 2013

A condensed statement of financial position of the Group at June 30, 2013 is provided below:

(in thousand of euros)	**6/30/2013**	**12/31/2012**
Intangible assets	122,839	125,276
Property, plant and equipment	63,919	65,316
Other non-current assets	23,085	22,400
Net working capital	145,934	137,640
Other non-current liabilities	(32,930)	(32,798)
Net invested capital	**322,847**	**317,834**
Net financial position	**56,750**	**47,168**
Shareholders' equity	**379,597**	**365,002**

Non-current assets decreased from 212,992 thousand euros at December 31, 2012 to 209,843 thousand euros at June 30, 2013, due to the period's depreciation of property, plant and equipment and amortization of intangibles and the translation effect resulting from fluctuations in the exchange rate for the euro versus the main currencies used by the Group, that largely offset the investments of the period.

A breakdown of net working capital is provided below:

(in thousands of euros)	**6/30/2013**	**12/31/2012**	**Change**
Trade receivables	121,085	113,788	7,297
Ending inventory	86,033	83,972	2,061
Trade payables	(35,611)	(37,206)	1,595
Other current assets/liabilities (1)	(25,573)	(22,914)	(2,659)
Net working capital	**145,934**	**137,640**	**8,294**

(1)Other current assets/liabilities is defined as the algebraic sum of receivables and payables other than financial and commercial items.

.

Working capital increased by 8,294 thousand euros in the first half of 2013, due mainly to a rise in trade receivables and inventories that were partially offset by the change of other current assets and liabilities. The increase of 7,297 thousand euros in trade receivables compared with December 31, 2012 reflects revenues positive trend (mainly Germany, Italy and Brazil) despite a deterioration in payment performance in European markets.
Ending inventories grew by 2,061 thousand euros compared with December 31, 2012 due to higher inventories of semi-finished goods at the Group's production facilities, for products whose launch is scheduled in the next months.
Other current assets/liabilities increased by 2,659 thousand euros, due to income tax liabilities and the use of tax credits recognized at December 31, 2012 during the first half of 2013.

At June 30, 2013 the net consolidated financial position was positive by 56,750 thousand euros for an increase of 9,582 thousand euros compared with December 31, 2012, due to the cash flow generated from operating activities in the first half of 2013, amounted to 37,395 thousand euros.

A condensed net financial position schedule is shown below:

(in thousands of euros)	**6/30/2013**	**12/31/2012**
Cash and cash equivalents	67,506	104,599
Liquid assets (a)	**67,506**	**104,599**
Other current financial assets (b)	**-**	**263**
Current bank debt	(8,104)	(8,047)
Other current financial liabilities	(2,123)	(19)
Current indebtedness (c)	**(10,227)**	**(8,066)**
Net current financial assets (d)=(a)+(b)+(c)	**57,279**	**96,796**
Non-current bank debt	(495)	(4,512)
Other non-current financial liabilities	(34)	(36)
Non-current indebtedness (e)	**(529)**	**(4,548)**
Liabilities to the shareholders for the dividend (f)	**-**	**(45,080)**
Net financial position (g)=(d)+(e)+(f)	**56,750**	**47,168**

Shareholders' equity, which totaled 379,597 thousand euros at June 30, 2013 (365,002 thousand euros at December 31, 2012), includes treasury shares valued at 44,882 thousand euros.
The reserve for treasury shares, which was established pursuant to law (Article 2357 of the Italian Civil Code), was recognized following purchases of treasury shares executed in 2011.

ANALYSIS OF CONSOLIDATED CASH FLOWS

A schedule showing a condensed consolidated statement of cash flows, followed by a review of the main statement items and of the changes that occurred compared with the corresponding period in 2012, is provided below:

(in thousand of euros)	**1st half 2013**	**1st half 2012**	**2nd quarter 2013**	**2nd quarter 2012**
Cash and cash equivalents at the beginning of period	**104,599**	**64,145**	**85,410**	**80,632**
Net cash from operating activities	48,744	54,918	18,646	32,618
Cash used for investing activities	(12,401)	(13,298)	(7,291)	(7,060)
Cash used for financing activities	(73,706)	(28,322)	(29,529)	(28,747)
Acquisitions of subsidiaries and business operations	270	(7,600)	270	(7,600)
Net change in cash and cash equivalents	***(37,093)***	***5,698***	***(17,904)***	***(10,789)***
Cash and cash equivalents at end of period	**67,506**	**69,843**	**67,506**	**69,843**

The cash flow from operating activities decreased from 54,918 thousand euros in the first half of 2012 to 48,744 thousand euros in the same period in 2013. The income stream (net profit plus depreciation and amortization, additions to provisions and other non-cash items) was lower (83,899 thousand euros) than in 2012 (86,761 thousand euros). In the first six months of 2012, working capital dynamic were more favorable than the previous year, due to the collection of past-due positions owed by public entities in the countries where the Group operates. Moreover, tax payments totaled 22,148 thousand euros (25,765 thousand euros in the first half of 2012).

Net cash used in investing activities totaled 12,401 thousand euros, compared with 13,298 thousand euros in the first six months of 2012: capital expenditures for medical equipment amounted to 9,027 thousand euros, compared with the first six months of 2012 (equal to 9,442 thousand euros), due to the introduction of LIAISON XL new analyzer. In addition, development costs of 1,514 thousand euros (1,650 thousand euros in the first half of 2012) were capitalized in the first six months of 2013, mainly in connection with investments in molecular diagnostics.

The cash used for financing activities totaled 73,706 thousand euros (28,322 in the same period last year). It was used mainly for a dividend distribution of 72,257 thousand euros in the first six months of 2013 (including 45,080 thousand euros for an extraordinary dividend distribution) and repayments of financing facilities amounting to 4,086 thousand euros.

Moreover, in May the Group cashed 270 thousand euros to adjust NorDiag business cost, acquired last year.

At June 30, 2013, available liquid assets held by the Group totaled 67,506 thousand euros down from 104,599 thousand euros at the end of 2012.

OTHER INFORMATION

The Group had 1,610 employees at June 30, 2013 (1,553 employees at December 31, 2012).

TRANSACTIONS WITH RELATED PARTIES

In the normal course of business, Diasorin S.p.A. engages on a regular basis in commercial and financial transactions with its subsidiaries, which are also Group companies. These transactions, which are part of the Group's regular operations and are executed on standard market terms, consist of the supply of goods and services, including administrative, information technology, personnel management, technical support and consulting services, which produce receivables and payables at the end of the year, and financing and cash management transactions, which produce income and expenses.

These transactions are eliminated in the consolidation process and, consequently, are not discussed in this section of this Report.

The Group awards additional benefits to several eligible employees of Diasorin S.p.A. and other Group companies through a stock option plan. The costs incurred in connection with this plan totaled 737 thousand euros in the first six months of 2013 (864 thousand euros in 2012)

The compensation payable to the key management and strategic management is consistent with standard market terms for compensation offered to employees with a similar status.

SIGNIFICANT EVENTS OCCURRING AFTER JUNE 30, 2013 AND BUSINESS OUTLOOK

In July, Diasorin received the marketing authorization for 5 LIAISON XL assays (HBsAg Quant, Anti-HBs II, HCV Ab, HIV Ab/Ag, recHTLV-I/II) related to Hepatitis and Retroviruses.
With the launch of the full panel of CLIA Hepatitis and Retroviruses assays, now available on the LIAISON XL, Diasorin completes the already available markers for Hepatitis B and Hepatitis A in CLIA technology and is now positioned as the only company providing a complete solution for blood banks in both CLIA and ELISA technology.

In July, the Group announced the launch of a new molecular diagnostic test for the detection of Toxoplasmosis in the context of infectious diseases on its LIAISON IAM analyzer, available on the market outside of the United States and Canada. The IAM Toxo is the fourth test launched by the Group to implement the panel of infectious diseases in molecular diagnostics already composed by the assays for the detection of infections from BK Virus, Varicella Zoster and Parvovirus (IAM BKV, VZV IAM, IAM PARVO) all marketed during the past few months.

On July 1, started the operating activity of Diasorin Switzerland, created in the first six months of 2013.

Among the significant events occurring after June 30, 2013, in the legal proceedings between Diasorin S.p.A and the license holder and distributor of the patent number EP09128989, the Court of Rome prohibited Diasorin S.p.A from manufacturing, marketing and using LIAISON tTg IgA kits, through an interlocutory judgment. The company was ordered to pay damages to the Counterparty. The extent of the damage has not been quantified. The company is adopting any necessary measure to comply with the Court's temporary decision.

In view of the Group's operating performance after June 30, 2013 and taking into account possible evolutions of the global macroeconomic scenario and the diagnostic sector in particular, management confirms the guidance already provided for the 2013 reporting year:

- Revenues: growth rate between 2% and 4% at CER compared with 2012. Molecular business would be equal about € 5 mln;
- EBITDA: in line with the absolute value of 2012 at CER, with an absorption from Molecular business equal to about € 6 mln, as a result of investments required in the development of the new business;
- LIAISON/LIAISON XL installed base: about 500.

CONDENSED SEMIANNUAL CONSOLIDATED FINANCIAL STATEMENTS AT JUNE 30, 2013

CONSOLIDATED INCOME STATEMENT

(in thousand of euros)	**notes**	**1st half 2013**	**1st half 2012**
Net revenues	(1)	219,719	220,686
Cost of sales	(2)	(67,828)	(67,405)
Gross profit		**151,891**	**153,281**
Sales and marketing expenses	(3)	(43,031)	(40,617)
Research and development costs	(4)	(12,187)	(11,757)
General and administrative expenses	(5)	(24,502)	(24,309)
Other operating income (expenses)	(6)	(2,588)	(1,852)
Non-recurring amount		-	*(853)*
EBIT		**69,583**	**74,746**
Net financial income/ (expense)	(7)	(2,869)	(1,645)
Profit before taxes		**66,714**	**73,101**
Taxes	(8)	(25.673)	(27,562)
Net profit for the period		**41,041**	**45,539**
Broken down as follows:			
Minority interest in net result		223	185
Group's Parent Company interest in net result		40,818	45,354
Earnings per share (basic)	(9)	**0.75**	**0.84**
Earnings per share (diluted)	(9)	**0.75**	**0.84**

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(in thousands of euros)	**1st half 2013**	**1st half 2012**
Net profit for the period (A)	**41,041**	**45,539**
Other comprehensive income that will not be reclassified subsequently to profit/(loss) of the period:		
Gains/(losses) on retirement benefit obligations	5	(703)
Total other comprehensive income that will not be reclassified subsequently to profit/(loss) of the period (B1)	**5**	**(703)**
Other comprehensive income that will be reclassified subsequently to profit/(loss) of the period:		
Gains/(losses) on exchange differences on translating foreign operations	(1,254)	1,477
Gains/(losses) on net investment hedge	158	(22)
Total other comprehensive income that will not be reclassified subsequently to profit/(loss) of the period (B2)	**(1,096)**	**1,455**
TOTAL OTHER COMPREHENSIVE INCOME, NET OF TAX (B1)+(B2)=(B)	**(1,091)**	**752**
TOTAL COMPREHENSIVE INCOME (A)+(B)	**39,950**	**46,291**
Including:		
- amount attributable to minority interests	237	194
- amount attributable to Parent Company shareholders	**39,713**	**46,097**

(*)Following the retrospective application of the amendment to IAS 19 from January 1, 2013 the comparative figures at June 30, 2012 have been restated as required by IAS 1. The relative effect compared with the previously reported figures reflects a decrease in the comprehensive income of the first half 2012 equal to 703 thousand euros. See section “New accounting principles” of the Report on operations for additional information.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(in thousands of euros)	**notes**	**6/30/2013**	**12/31/2012 (*)**
ASSETS			
Non-current assets			
Property, plant and equipment	(10)	63,919	65,316
Goodwill	(11)	66,990	67,689
Other intangibles	(11)	55,849	57,587
Equity investments	(12)	513	177
Deferred-tax assets	(13)	20,430	21,342
Other non-current assets	(14)	2,142	881
Total non-current assets		*209,843*	*212,992*
Current assets			
Inventories	(15)	86,033	83,972
Trade receivables	(16)	121,085	113,788
Other current financial assets	(20)	-	263
Other current assets	(17)	9,410	10,540
Cash and cash equivalent	(18)	67,506	104,599
Total current assets		*284,034*	*313,162*
TOTAL ASSETS		**493,877**	**526,154**

(*)Following the retrospective application of the amendment to IAS 19 from January 1, 2013 the comparative figures at December 31, 2012 have been restated as required by IAS 1. More specifically, the figure for deferred tax assets reported in the Consolidated Financial Statements at 31 December 2012 has increased by 1,134 thousand euros. See section "New accounting principles" of the Report on operations for additional information.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION *(continued)*

(in thousands of euros)	**notes**	**6/30/2013**	**12/31/2012 (*)**
LIABILITIES AND SHAREHOLDERS' EQUITY			
Shareholders' equity			
Share capital	(19)	55,908	55,863
Additional paid-in capital	(19)	17,007	15,967
Statutory reserve	(19)	11,181	11,168
Other reserves and retained earnings	(19)	298,834	238,996
Treasury stock		(44,882)	(44,882)
Net profit for the period attributable to shareholders of the Parent Company		40,818	87,396
Shareholders' equity attributable to shareholders of the Parent Company		*378,866*	*364,508*
Other reserves and retained earnings attributable to minority interests		508	206
Net profit for the year attributable to minority interests		223	288
Shareholders' equity attributable to minority interests		*731*	*494*
Total shareholders' equity		**379,597**	**365,002**
Non-current liabilities			
Long-term borrowings	(20)	529	4,548
Provisions for employee severance indemnities and other employee benefits	(21)	26,073	25,802
Deferred-tax liabilities	(13)	3,448	3,579
Other non-current liabilities	(22)	3,409	3,417
Total non-current liabilities		*33,459*	*37,346*
Current liabilities			
Trade payables	(23)	35,611	37,206
Other current liabilities	(24)	24,630	24,572
Liabilities to the shareholders for the dividend	(24)	-	45,080
Taxes payable	(25)	10,353	8,882
Current portion of medium and long-term debt	(20)	8,122	8,066
Other financial liabilities	(20)	2,105	-
Total current liabilities		*80,821*	*123,806*
Total liabilities		**114,280**	**161,152**
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		**493,877**	**526,154**

(*)Following the retrospective application of the amendment to IAS 19 from January 1, 2013 the comparative figures at December 31, 2012 have been restated as required by IAS 1. More specifically, the figure for employee benefit plans reported in the Consolidated Financial Statements at December 31, 2012 has increased by 4,213 thousand euros and the figure for closing Shareholders' equity has decreased by 3,079 thousand euros, relating to closing Shareholders' equity attributable to owners of the Group Parents company. See section "New accounting principles" of the Report on operations for additional information.

CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands of euros)	**1st half 2013**	**1st half 2012**
Cash flow from operating activities		
Net profit for the period	41,041	45,539
Adjustment for:		
- Income taxes	25,673	27,562
- Depreciation and amortization	14,290	14,140
- Financial expense/ (income)	2,869	1,645
- Additions to/ (Utilizations of) provisions for risk	38	(1,283)
- (Gains)/Losses on sales of non-current assets	50	63
- Additions to/(Reversals of) provisions for employee severance indemnities	90	288
- Changes in shareholders' equity reserves:		
- Stock option reserve	737	864
- Cumulative translation adjustment from operating activities	(278)	941
- Change in other non current-assets/liabilities	(611)	(2,998)
Cash flow from operating activities before changes in working capital	**83,899**	**86,761**
(Increase)/Decrease in receivables included in working capital	(7,903)	1,045
(Increase)/Decrease in inventories	(2,892)	(2,823)
Increase/(Decrease) in trade payables	(1,482)	(1,712)
(Increase)/Decrease in other current items	322	(1,476)
Cash from operating activities	**71,944**	**81,795**
Income taxes paid	(22,148)	(25,765)
Interest paid	(1,052)	(1,112)
Net cash from operating activities	**48,744**	**54,918**
Investments in intangibles	(2,159)	(2,169)
Investments in property, plant and equipment	(12,171)	(12,419)
Retirements of property, plant and equipment	1,929	1,290
Cash used in regular investing activities	**(12,401)**	**(13,298)**
Acquisitions of subsidiaries and business operations	270	(7,600)
Cash used in investing activities	**(12,131)**	**(20,898)**
(Repayment of)/Proceeds from Loan and other financial obligations	(2,086)	(4,548)
Increase in share capital and additional paid-in capital/Dividend distribution	(71,172)	(22,755)
Equity investments	(495)	-
Foreign exchange translation effect	47	(1,019)
Cash used in financing activities	**(73,706)**	**(28,322)**
Net change in cash and cash equivalents	**(37,093)**	**5,698**
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	**104,599**	**64,145**
CASH AND CASH EQUIVALENTS AT END OF PERIOD	**67,506**	**69,843**

STATEMENT OF CHANGES IN CONSOLIDATED SHAREHOLDERS' EQUITY

(in thousands of euros)	Share capital	Additional paid-in capital	Statutory reserve	Cumulative translation reserve	Stock Option Reserve	Reserve for treasury stock	OCI Reserve	Retained earnings (Accumulated deficit)	Treasury stock	Net profit for the period	Group interest in shareholders' equity	Minority interest in equity	Total interest in shareholders'equity
Shareholders' equity at 12/31/2011(*)	**55,698**	**13,744**	**8,016**	**8,137**	**2,337**	**44,882**	**(1,673)**	**163,570**	**(44,882)**	**99,465**	**349,294**	**211**	**349,505**
Appropriation of previous year's profit	-	-	3,152	-	-	-	-	96,313	-	(99,465)	**-**		**-**
Dividends distribution	-	-	-	-	-	-	-	(24,971)	-	-	**(24,971)**		**(24,971)**
Capital increase	157	2,059	-	-	-	-	-	-	-	-	**2,216**		**2,216**
Stock options and other changes	-	-	-	-	324	-	-	540	-	-	**864**		**864**
Translation adjustment	-	-	-	1,468	-	-	-	-	-	-	**1,468**	**9**	**1,477**
Actuarial gains/losses on employee benefits recognized directly in other comprehensive income	-	-	-	-	-	-	(703)	-	-	-	**(703)**		**(703)**
Net investment hedge gains/(losses), net of tax effect	-	-	-	(22)	-	-	-	-	-	-	**(22)**		**(22)**
Net profit for the period	-	-	-	-	-	-	-	-	-	45,354	**45,354**	**185**	**45,539**
Shareholders' equity at 6/30/2012(*)	**55,855**	**15,803**	**11,168**	**9,583**	**2,661**	**44,882**	**(2,376)**	**235,452**	**(44,882)**	**45,354**	**373,500**	**405**	**373,905**
Shareholders' equity at 12/31/2012(*)	**55,863**	**15,967**	**11,168**	**3,463**	**3,336**	**44,882**	**(3,079)**	**190,394**	**(44,882)**	**87,396**	**364,508**	**494**	**365,002**
Appropriation of previous year's profit	-	-	13	-	-	-	-	87,383	-	(87,396)	**-**		**-**
Dividends distribution	-	-	-	-	-	-	-	(27,177)	-	-	**(27,177)**		**(27,177)**
Capital increase	45	1,040	-	-	-	-	-	-	-	-	**1,085**		**1,085**
Stock options and other changes	-	-	-	-	469	-	-	268	-	-	**737**		**737**
Translation adjustment	-	-	-	(1,268)	-	-	-	-	-	-	**(1,268)**	**14**	**(1,254)**
Actuarial gains/losses on employee benefits recognized directly in other comprehensive income	-	-	-	-	-	-	5	-	-	-	**5**		**5**
Net investment hedge gains/(losses), net of tax effect	-	-	-	158	-	-	-	-	-	-	**158**		**158**
Net profit for the period	-	-	-	-	-	-	-	-	-	40,818	**40,818**	**223**	**41,041**
Shareholders' equity at 6/30/2013	**55,908**	**17,007**	**11,181**	**2,353**	**3,805**	**44,882**	**(3,074)**	**250,868**	**(44.882)**	**40,818**	**378,866**	**731**	**379,597**

(*)Following the retrospective application of the amendment to IAS 19 from January 1, 2013 the comparative figures at January 1 and December 31, 2012 have been restated as required by IAS 1. More specifically, the figure for closing Shareholders' equity has decreased by 3,079 thousand euros, relating to closing Shareholders' equity attributable to owners of the Group Parents company. See section "New accounting principles" of the Report on operations for additional information.

NOTES TO THE CONDENSED SEMIANNUAL CONSOLIDATED FINANCIAL STATEMENT AT JUNE 30, 2013 AND JUNE 30, 2012

GENERAL INFORMATION AND SCOPE OF CONSOLIDATION

General information

The Diasorin Group specializes in the development, manufacture and distribution of products in the immunochemistry and infectious immunology product groups. These product classes can also be grouped into a single family called immunodiagnostics. Diasorin S.p.A., the Group's Parent Company, has its headquarters on Via Crescentino (no building number), in Saluggia (VC).

Principles for the preparation of the condensed semiannual consolidated financial statements

These condensed semiannual consolidated financial statements were prepared in compliance with the International Financial Reporting Standards ("IFRSs"), as issued by the International Accounting Standards Board ("IASB") and adopted by the European Union. The designation IFRSs also includes the International Accounting Standards ("IASs") that are still in effect and all of the interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

This Semiannual Report was prepared in accordance with the requirements of the relevant international accounting standard (IAS 34 – Interim Financial Reporting).
These notes provide information in summary form, in order to avoid duplicating information published previously, as required by IAS 34. Specifically, these notes discuss only those components of the income statement and balance sheet the composition or change in amount of which require comment (due to the amount involved or the type of transaction or because an unusual transaction is involved) in order to understand the Group's operating performance, financial performance and financial position.

Consequently, these condensed semiannual consolidated financial statements do not provide all of the disclosure required in the annual financial statements and should be read in conjunction with the annual financial statements prepared for the year ended December 31, 2012.

When preparing interim financial statements, management is required to develop estimates and assumptions that affect the amounts shown for revenues, expenses, assets and liabilities in the financial statements and the disclosures provided with regard to contingent assets and liabilities on the date of the interim financial statements. If such estimates and assumptions, which were based on management's best projections, should differ from actual events, they will be modified appropriately when the relevant events produce the abovementioned differences.

As a rule, certain valuation processes, particularly the more complex processes such as determining whether the value of non-current assets has been impaired, are carried out fully only in connection with the preparation of the annual financial statements, when all the necessary information is available, except when there are impairment indicators that require an immediate evaluation of any impairment losses that may have occurred.

The process of preparing the condensed semiannual consolidated financial statements included developing the actuarial valuation required to compute the provisions for employees benefits and value the stock option plan.
The income tax liability is recognized using the best estimate of the weighted average tax rate projected for the entire year.
In this Consolidated Semiannual Report, all amounts are in thousands of euros unless otherwise stated.

New accounting principles

On June 16, 2011, the IASB issued an amendment to IAS 1 – *Presentation of Financial Statements* requiring companies to group items presented in comprehensive income on the basis of whether they are potentially reclassifiable to profit or loss subsequently. The amendment is applicable for periods beginning on or after July 1, 2012; the Group has applied this amendment since January 1, 2013. The application of this amendment had no effect on the measurement of items and had a limited effect on the disclosures provided in this Semiannual Report.

On December 16, 2011, the IASB issued certain amendments to IFRS 7 – *Financial Instruments*: Disclosures. The amendments require information about the effect or potential effect of netting arrangements for financial assets and liabilities on an entity's financial position. The amendments are applicable for periods beginning on or after January 1, 2013 and subsequent interim reporting periods. Applying these amendments has not had effects on the disclosures presented in this Semiannual Report.

On May 12, 2011, the IASB issued IFRS 13 – *Fair Value Measurement*, which clarifies the determination of fair value for the purpose of the financial statements and is applicable to all IFRSs permitting or requiring a fair value measurement or the presentation of disclosures based on fair value. The Group has prospectively applied this standard from January 1, 2013. The application of this standard did not have any effect on the measurement of items in this Semiannual Report.

On June 16, 2011, the IASB issued an amendment to IAS 19 – *Employee Benefits,* which eliminates the option of deferring the recognition of actuarial gains or losses by the corridor method, requiring instead the presentation in the statement of financial position of the full amount of any deficit or surplus in the provision, the separate recognition in the income statement of cost components related to employee service and net financial expense, and the recognition of actuarial gains or losses resulting from the annual measurement of assets and liabilities as other comprehensive income/ (loss). In addition, the return on assets included in net financial expense must be computed based on the discount rate applied to liabilities and no longer on the assets' expected rate of return. Lastly, the amendment introduces new additional disclosures to be provided in the notes to the financial statements. In accordance with the transition rules in IAS 19, paragraph 173, the Parent Company applied this amendment retrospectively as of the reporting period beginning on January 1, 2013, by adjusting the values of openness of financial position at January 1, 2012 and at December 31, 2012 and the comprehensive income statement of 2012 s if the amendments to IAS 19 had always been applied. In detail, the Group determined the final effects due to the adoption of the amendment, as follows:

(in thousands of euros)	Amounts as previously reported	IAS 19 revised adoption effect	Amounts as restated
			At January 1, 2012
Effects on the statement of financial position:			
Deferred-tax assets	20,119	544	20,663
Provisions for employee severance indemnities and other employee benefits	20,948	2,217	23,165
Total shareholders' equity:	351,178	(1,673)	349,505
Shareholders' equity attributable to shareholders of the Parent Company	350,967	(1,673)	349,294
Shareholders' equity attributable to minority interests	211	-	211

(in thousands of euros)	Amounts as previously reported	IAS 19 revised adoption effect	Amounts as restated
			At December 31, 2012
Effects on the statement of financial position:			
Deferred-tax assets	20,208	1,134	21,342
Provisions for employee severance indemnities and other employee benefits	21,589	4,213	25,802
Total shareholders' equity:	368,081	(3,079)	365,002
Shareholders' equity attributable to shareholders of the Parent Company	367,587	(3,079)	364,508
Shareholders' equity attributable to minority interests	494	-	494

(in thousands of euros)	Amounts as previously reported	IAS 19 revised adoption effect	Amounts as restated
			1st half 2012
Effects on the comprehensive income statement:			
Profit/(loss) for the period	45,539	-	45,539
Profit/(loss) on employee benefits	-	(703)	(703)
Total comprehensive profit/(loss) that will not be reclassified in profit/(loss) of the period	-	(703)	(703)
Total comprehensive profit/(loss) that will be reclassified in profit/(loss) of the period	1,455	-	1,455
TOTAL COMPREHENSIVE PROFIT/(LOSS)	46,994	(703)	46,291

On May 17, 2012, the IASB issued a set of amendments to IFRSs ("Annual Improvements to IFRSs 2009-2011 Cycle"), to be applied retrospectively from January 1, 2013; set out below are those applicable to the Group, excluding those that only regard changes in terminology having a limited accounting effect:

- IAS 1 – Presentation of Financial Statements: the amendment clarifies the way in which comparative information should be presented when an entity changes accounting policies and when an entity provides comparative information in addition to the minimum

comparative financial statements. This amendment was applied for assets and liabilities in accordance with the application of IAS 19, as the table above show.

- IAS 16 – Property, plant and equipment: the amendment clarifies that the spare parts and replacement equipment must be capitalized only if they comply with the definition of property, plant and equipment, or should be classified as inventories. The application of this amendment had no effect on the measurement of items provided in this Semiannual Report.

- IAS 32 – Financial Instruments: Presentation: the amendment eliminates an inconsistency between IAS 12 – *income tax* and IAS 32 *on tax collection* arising from distributions to shareholders that should be recognized in the income statement to the extent that the distribution refers to revenue generated from transactions originally entered in the income statement. The application of this amendment had no effect on the measurement of items provided in this Semiannual Report.

Financial statement presentation formats

The financial statements are presented in accordance with the following formats:

- In the income statement, costs are broken down by function. This income statement format, also known as a "cost of sales" income statement, is more representative of the Group's business than a presentation with expenses broken down by nature because it is consistent with internal reporting and business management methods and with international practice in the diagnostic industry;
- In the statement of financial position, current and non-current assets and current and non-current liabilities are shown separately;
- The statement of cash flows is presented in accordance with the indirect method.

Scope of consolidation

These condensed semiannual consolidated financial statements include the financial statements of Diasorin S.p.A., the Group's Parent Company, and those of its subsidiaries.

Subsidiaries are companies over which the Group is able to exercise control, i.e., it has the power to determine their operating and financial policies, so as to obtain benefits from the results of their operations.

Subsidiaries are consolidated line by line from the date the Group obtains control until the moment when control ceases to exist. Dormant subsidiaries are not consolidated.

In the first half of 2013, no change in scope of consolidation occurred.

A list of the subsidiaries included in the scope of consolidation, complete with information about head office locations and the percentage interest held by the Group, is provided in Annex I.

ANALYSIS OF FINANCIAL RISKS

The financial risks to which the Group is exposed include market risk and, to a lesser extent, credit risk and liquidity risk.

As required by IAS 39, assets and liabilities of a material amount are listed below:

		6/30/2013				12/31/2012			
(in thousands of euros)	**Notes**	**Carrying amount**	**Receiv-ables**	**Hedging instru-ments**	**Held for trading**	**Carryin g amount**	**Receiv-ables**	**Hedging instru-ments**	**Held for trading**
Trade receivables	(16)	121,085	121,085	-	-	113,788	113,788	-	-
Other current financial assets	(20)	-	-	-	-	263	-	-	263
Cash and cash equivalents	(18)	67,506	67,506	-	-	104,599	104,599	-	-
Total current financial assets		***188,591***	***188,591***	***-***	***-***	***218,650***	***218,387***	***-***	***263***
Total financial assets		**188,591**	**188,591**	**-**	**-**	**218,650**	**218,387**	**-**	**263**

		6/30/2013				12/31/2012			
(in thousands of euros)	**Notes**	**Carryin g amount**	**Liabilities at amor-tized cost**	**Hedging instru-ments**	**Held for trading**	**Carryin g amount**	**Liabilities at amor-tized cost**	**Hedging instru-ments**	**Held for trading**
Long-term borrowings	(20)	529	529	-	-	4,548	4,548	3,235	-
Total non-current financial liabilities		***529***	***529***	***-***	-	***4,548***	***4,548***	***3,235***	***-***
Trade payables	(23)	35,611	35,611	-	-	37,206	37,206		-
Current portion of long-term debt	(20)	8,122	8,122	6,529	-	8,066	8,066	6,472	-
Other current financial liabilities	(20)	2,105	2,000	-	105	-	-	-	-
Liabilities to the shareholders for the dividend	(24)	-	-	-	-	45,080	45,080	-	-
Total current financial liabilities		***45,838***	***45,733***	***6,529***	***105***	***90,352***	***90,352***	***6,472***	***-***
Total financial liabilities		**46,367**	**46,262**	**6,529**	**105**	**94,900**	**94,900**	**9,707**	**-**

Risks related to fluctuations in foreign exchange and interest rates

At June 30, 2013, reference borrowings totaled 10,756 thousand euros. Considering the company's low level of borrowings, a change of 2 percentage points in interest rates on medium and long-term borrowings would have no impact on the income statement.
An increase or decrease of 2 percentage points in the Euribor on all of the receivables assigned without recourse to the factoring company (22,744 thousand euros in the first half of 2013) would result in a change in financial expense of 0.4 million euros.

The Group is exposed to the market risk caused by fluctuations in foreign exchange rates because it operates at the international level and executes transactions involving different foreign exchange and interest rates. The Group's exposure to foreign exchange risks is due to the geographic distribution of its production facilities and of the markets where it sells its products and to the use of external sources to secure financing in foreign currencies.

Starting in the first quarter of 2010, the Company applies the guidelines of IAS 39 to account for a hedge of a net investment. Specifically, a financing facility provided to the Group's Parent Company in U.S. dollars has been designated as an instrument hedging net assets denominated in U.S. dollars, as allowed by IAS 39. The effectiveness of this hedge is verified every three months using the dollar offset

method. The portion that this test shows to be effective is reflected in shareholders' equity under the translation reserve. This item will continue to be part of shareholders' equity until the Company decides to dispose of the U.S. operations.
However, in terms of the financial expense recognized in the income statement upon the translation of other debt denominated in foreign currencies, the impact on the income statement of an increase or decrease of 5 percentage points in the euro/U.S. dollar exchange rate would amount to 0.3 million euros. Moreover, the impact on the income statement of an increase or decrease of 5 percentage points in the euro/British pound exchange rate would amount to about 0.4 million euros.

Since the Group's reporting currency is the euro, the income statements of subsidiaries located in countries that are not members of the European Monetary Union are translated into euros at the average exchange rate for the period. Consequently, even if revenues and margins were to remain equal when stated in the local currency, fluctuations in exchange rates could have an impact on the euro amount of revenues, expenses and operating results due to the translation into the consolidation currency. A 5% change in the exchange rates of all of the currencies used by the Group would have an impact on the income statement of about 1 million euros.

The euro amount attributed to assets and liabilities of consolidated companies that use reporting currencies different from the euro could vary as a result of changes in exchange rates. As required by the accounting principles adopted by Diasorin, these changes are recognized directly in equity by posting them to the currency translation reserve. A 5% change in all foreign exchange rates would have an impact of about 6 million euros on the currency translation reserve.

The Group monitors any significant exposures to the foreign exchange translation risk. However, no hedges had been established against such exposures as of the date of the financial statements. This is because the potential impact of the foreign exchange translation risk on the Group's equity is not significant.

Credit risk

The Group's receivables present a low level of risk since most of these receivables are owed by public institutions, for which the risk of non-collection is negligible.
At June 30, 2013, past-due trade receivables were equal to about 23% of revenues. These receivables were held mainly by the Group's Parent Company and the Spanish and Brazilian subsidiaries, which sell a very high percentage of their products to the local national health services. About 65% of these receivables was more than 120 days past due. These past-due receivables are covered by an allowance for doubtful accounts amounting to 8,083 thousand euros. In addition, in order to bridge the gap between contractual payment terms and actual collection dates, the Group assigns its receivables to factors without recourse.

Liquidity risk

A prudent cash management strategy includes maintaining sufficient cash or readily available assets, as well as credit lines, to meet immediate liquidity needs. Cash flows, funding requirements and liquidity levels are monitored and managed centrally to ensure promptly and effectively the availability of financial resources and invest appropriately any excess liquidity.
Management believes that the funds and credit lines currently available, when combined with the resources generated by operating and financing activities, will enable the Group to meet the obligations resulting from its capital investment programs, working capital requirements and the need to repay its indebtedness upon maturity.

Commercial Risk

The Diasorin Group is subject to the commercial risk, particularly with regard to the Vitamin D segment, caused by increased competition and the market entry, both in the United States and in Europe, of such aggressive competitors as Siemens, Abbot and Roche. The strategy of protecting major customers by extending long-term contracts, the acknowledged extremely high quality of Diasorin tests, the ability of doubling the hourly rate of determinations offered by the LIAISON XL, and growing demand in countries where dosage is still not very frequent ensure that Diasorin will continue to play a leading role in the future of this market. In addition, a positive trend in sales of all other LIAISON specialties offset in part weakness in other segments, including that of Vitamin D.

Other information

Information about significant events occurring after June 30, 2013, the Group's business outlook and its transactions with related parties is provided in separate sections of this Semiannual Report.
The table below provides a comparison of the average and end-of-period exchange rates for the first half of 2013 and 2012 (source: Italian Foreign Exchange Bureau):

Currency	**Average rates for**				**Rates at**	
	1st half 2013	**1st half 2012**	**2nd quarter 2013**	**2nd quarter 2012**	**6/30/2013**	**6/30/2012**
U.S. dollar	1.3134	1.2965	1.3062	1.2814	1.3080	1.2590
Brazilian real	2.6683	2.4144	2.6994	2.5167	2.8899	2.5788
British pound	0.8508	0.8225	0.8506	0.8100	0.8572	0.8068
Swedish kronor	8.5311	8.8824	8.5652	8.9133	8.7773	8.7728
Czech koruna	25.6994	25.1742	25.8313	25.2693	25.9490	25.6400
Canadian dollar	1.3341	1.3040	1.3368	1.2949	1.3714	1.2871
Mexican peso	16.4982	17.1867	16.2956	17.3620	17.0413	16.8755
Israeli shekel	4.8182	4.9231	4.7407	4.9021	4.7386	4.9453
Chinese Yuan	8.1285	8.1901	8.0376	8.1072	8.0280	8.0011
Australian dollar	1.2961	1.2559	1.3203	1.2699	1.4171	1.2339
South African rand	12.1153	10.2942	12.3996	10.4214	13.0704	10.3669

OPERATING SEGMENTS

As required by IFRS 8, the Company designated the geographic regions where it operates as its operating segments.

The Group's organization and internal management structure and its reporting system identify the following segments: Italy and UK Branch, Europe (Germany, France, Belgium and the Netherlands, Spain and Portugal, Ireland, Austria, Great Britain, Scandinavia, Czech Republic), North America (United States and Canada) and Rest of the World (Brazil, Mexico, Israel, China, Australia and South Africa).

The Group is characterized by a structure of its commercial organization based geographic regions, which was developed to address the requirements created by geographic expansion and strategic initiatives, such as the launch of the LIAISON XL. This new organization, which was conceived to reflect the destinations of the Group's sales, is based on the following four regions: Europe and Africa, North America, Central and South America, and Asia Pacific (including China).

As a result, the financial data of the Diasorin Group that are being disclosed to the financial markets and the investing public now include revenue information that reflects the regional organization mentioned above.

The schedules that follow show the Group's operating and financial data broken down by geographic region. Information about revenues based on customer locations is provided in the Report on operations, in the comments to the schedule showing a breakdown of net revenues by geographic region.

No unallocated common costs are shown in the abovementioned schedules because the operations in each country (hence, each segment) are equipped with comprehensive independent organizations (sales, technical support and accounting) fully capable of exercising their functions. Moreover, the Italy segment invoices each quarter to the other segments the costs that are incurred centrally (mainly insurance costs and costs related to the Group's IT systems and management personnel).

Eliminations refer mainly to inter-segment margins that are eliminated upon consolidation. Specifically, the elimination of the margin earned by the Italy segment on the sale of equipment to other segments is shown both at the result level and with regard to capital expenditures. The margins earned on products sold by manufacturing facilities to sales branches that have not yet been sold to customers are eliminated only at the result level.

Segment assets include all items related to operations (non-current assets, receivables and inventories), but do not include tax related items (deferred-tax assets) and financial assets, which are shown at the Group level.
The same approach was used for segment liabilities, which include items related to operations (mainly trade payables and amounts owed to employees), but do not include financial and tax liabilities and shareholders' equity items, which are shown at the Group level.

	ITALY		EUROPE		NORTH AMERICA		REST OF THE WORLD		ELIMINATIONS		CONSOLIDATED	
(in thousands of euros)	**2013**	**2012**	**2013**	**2012**	**2013**	**2012**	**2013**	**2012**	**2013**	**2012**	**2013**	**2012**
INCOME STATEMENT												
Revenues from customers	59,568	55,524	60,458	58,267	57,357	68,175	42,336	38,720	-	-	219,719	220,686
Inter-segment revenues	53,058	53,998	14,668	14,637	13,650	13,684	1,826	3,655	(83,202)	(85,974)	-	-
Total revenues	**112,626**	**109,522**	**75,126**	**72,904**	**71,007**	**81,859**	**44,162**	**42,375**	**(83,202)**	**(85,974)**	**219,719**	**220,686**
Segment result	**23,558**	**17,762**	**5,727**	**8,453**	**37,136**	**46,018**	**3,272**	**4,682**	**(110)**	**(2,169)**	**69,583**	**74,746**
Unallocated common costs	-	-	-	-	-	-	-	-	-	-	-	-
EBIT	-	-	-	-	-	-	-	-	-	-	**69,583**	**74,746**
Other income (expense), net	-	-	-	-	-	-	-	-	-	-	-	-
Financial income (expense)	-	-	-	-	-	-	-	-	-	-	(2,869)	(1,645)
Result before taxes	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**66,714**	**73,101**
Income taxes	-	-	-	-	-	-	-	-	-	-	(25,673)	(27,562)
Net result	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**41,041**	**45,539**
OTHER INFORMATION												
Investments in intangibles	721	590	606	978	715	475	117	126	-	-	2,159	2,169
Invest. in prop., plant and equip.	4,481	3,564	4,445	4,444	1,570	3,669	3,231	3,172	(1,556)	(2,430)	12,171	12,419
Total investments	**5,202**	**4,154**	**5,051**	**5,422**	**2,285**	**4,144**	**3,348**	**3,298**	**(1,556)**	**(2,430)**	**14,330**	**14,588**
Amortization of intangibles	(1,768)	(1,799)	(1,371)	(1,041)	(211)	(178)	(372)	(651)	-	-	(3,722)	(3,669)
Amortization of prop., plant and equip.	(3,719)	(4,028)	(3,496)	(3,204)	(2,490)	(2,276)	(2,285)	(2,212)	1,422	1,249	(10,568)	(10,471)
Total amortization	**(5,487)**	**(5,827)**	**(4,867)**	**(4,245)**	**(2,701)**	**(2,454)**	**(2,657)**	**(2,863)**	**1,422**	**1,249**	**(14,290)**	**(14,140)**

	ITALY		EUROPE		NORTH AMERICA		REST OF THE WORLD		ELIMINATIONS		CONSOLIDATED	
	6/30/2013	**12/31/2012**	**6/30/2013**	**12/31/2012**	**6/30/2013**	**12/31/2012**	**6/30/2013**	**12/31/2012**	**6/30/2013**	**12/31/2012**	**6/30/2013**	**12/31/2012**
STATEMENT OF FINANCIAL POSITION												
Segment assets	230,520	222,558	118,391	110,130	70,596	73,625	56,629	57,877	(70,708)	(64,417)	405,428	399,773
Unallocated assets	-	-	-	-	-	-	-	-	-	-	88,449	126,381
Total assets	**230,520**	**222,558**	**118,391**	**110,130**	**70,596**	**73,625**	**56,629**	**57,877**	**(70,708)**	**(64,417)**	**493,877**	**526,154**
Segment liabilities	52,773	99,165	74,594	72,102	9,609	10,511	30,474	28,950	(77,727)	(74,651)	89,723	136,077
Unallocated liabilities	-	-	-	-	-	-	-	-	-	-	24,557	25,075
Shareholders' equity	-	-	-	-	-	-	-	-	-	-	379,597	365,002
Total liabilities and shareholders' equity	**52,773**	**99,165**	**74,594**	**72,102**	**9,609**	**10,511**	**30,474**	**28,950**	**(77,727)**	**(74,651)**	**493,877**	**526,154**

	EUROPA AND AFRICA		NORTH AMERICA		CENTRAL AND SOUTH AMERICA		ASIA/PACIFIC		CONSOLIDATED	
(in thousands of euros)	**2013**	**2012**	**2013**	**2012**	**2013**	**2012**	**2013**	**2012**	**2013**	**2012**
INCOME STATEMENT										
Revenues from customers	106,089	102,229	54,204	65,580	25,091	22,193	34,335	30,684	**219,719**	**220,686**

DESCRIPTION AND MAIN CHANGES

Consolidated income statement

The notes to the consolidated income statement are provided below. More detailed information about the components of the income statement is provided in the Report on Operations.

(1) Net revenues

In the first six months of 2013, net revenues, which are generated mainly through the sale of diagnostic kits, totaled 219,719 thousand euros, in line with 2012 data, equal to 220,686 thousand euros. Net revenues in the first half of 2013 include 3,812 thousand euros for equipment rentals and technical support revenues (3,767 thousand euros in the first half of 2012).

(2) Cost of sales

In the first half of 2013, the cost of sales amounted to 67,828 thousand euros compared with 67,405 thousand euros in the first half of 2012. The cost of sales includes 3,351 thousand euros in royalty expense (5,396 thousand euros in the same period last year) and 4,039 thousand euros in costs incurred to distribute products to end customers (4,085 in the first quarter of 2012). The cost of sales also includes the depreciation of medical equipment held by customers, which amounted to 7,391 thousand euros (6,798 thousand euros in the same period last year).

(3) Sales and marketing expenses

Sales and marketing expenses totaled 43,031 thousand euros in the first half of 2013, compared with 40,617 thousand euros in the first half of 2012, due mainly to the contribution of the molecular business, in start up phase.
This item consists mainly of marketing costs incurred to promote and distribute Diasorin products, costs attributable to the direct and indirect sales force and the cost of the technical support offered together with the Group-owned equipment provided to customers under gratuitous loan contracts.

(4) Research and development costs

The research and development costs incurred during the first half of 2013, which totaled 12,187 thousand euros (11,757 thousand euros in the same period in 2012), include all of the research and development outlays that were not capitalized (7,420 thousand euros compared with 7,272 thousand euros in the first quarter of 2012), the costs incurred to register the products offered for sale and meet quality requirements amounting to 3,838 thousand euros, (3,603 thousand euros in the first half of 2012) and the amortization of capitalized development costs equal to 929 thousand euros (882 thousand euros in the first half of 2012), including the amortization of LIAISON XL development. In the first six months of 2013, the Group capitalized new development costs amounting to 1,514 thousand euros compared with 1,650 thousand euros in the first half of 2012.

(5) General and administrative expenses

General and administrative expenses, which include expenses incurred for corporate management activities, Group administration, finance and control, information technology, corporate organization and insurance, totaled 24,502 thousand euros in the first half of 2013, in line with 2012 results.

(6) Other operating income (expense)

Net other operating expense totaled 2,588 thousand euros, compared with net other operating expense of 1,852 thousand euros in the first half of 2012. This item reflects other income from operations that does not derive from the Group's regular sales activities (such as gains on asset sales, government grants and insurance settlements), net of other operating charges that cannot be allocated to specific functional areas (losses on asset sales, out-of-period charges, indirect taxes and fees, and additions to provisions for risks).
Specific charges include additions to the allowance for doubtful accounts amounting to 457 thousand euros (207 thousand euros in the first six months of 2012) and 600 thousand euros in trade related foreign exchange translation losses (801 thousand euros in the first half of 2012) and 1,107 thousand euros in tax expenses (386 thousand euros in the first six months of 2012).

(7) Net financial income (expense)

The table below provides a breakdown of financial income and expense:

(in thousands of euros)	**1st half 2013**	**1st half 2012**
Interest and other financial expense	(1,502)	(1,536)
Valuation of financial instruments as per IAS 39	(368)	(373)
Cumulative share of OCI of entities consolidated under the equity method	(159)	-
Interest on pension funds	(418)	(417)
Interest and other financial income	483	467
Net translation adjustment	(905)	214
Net financial income (expense)	**(2,869)**	**(1,645)**

In the first half of 2013, net financial expense totaled 2,869 thousand euros, as against net financial expense of 1,645 thousand euros in the same period last year.

The main reason for this negative change is the effect of the translation adjustments of the period, negative of 905 thousand euros in the first half of 2013 (positive of 214 thousand euros in the first half of 2012), related mainly to the Euro exchange rate in the intercompany financing disbursed by the Group's Parent company to the Australian subsidiary in the local currency (538 thousand euros), together with the financial transactions of subsidiaries that use currencies different from that of the Group's Parent Company.

The fair value of financial instruments at June 30, 2013 was negative by 368 thousand euros, compared with 373 thousand euros in 2012.

Interests and other financial expense for the period included 1,098 thousand euros in factoring transaction fees (1,133 thousand euros in the first half of 2012).

The evaluation of investments in JV Diasorin Trivitron Healthcare Private Limited carried out on the basis of the equity method led to a loss in investments equal to 159 thousand euros in the first half of 2013.

(8) Income taxes

The income tax expense recognized in the income statement for the first six months of 2013 amounted to 25,673 thousand euros (27,652 thousand euros in the same period in 2012). The tax expense amount includes non-deductible foreign taxes withheld on the dividends paid to the

Group's Parent Company by the subsidiaries in U.S., South Africa and Israel for a total of 1,564 thousand euros in the first half of 2013 (1,685 thousand euros in the first half of 2012).
In the first half of 2013, the tax burden was equal to 38.5% of the profit before taxes (37.7% in the first half in 2012).

(9) Earnings per share

Basic earnings per share, which amounted to 0.75 euros in the first quarter of 2013, compared with 0.84 euros in the same period in 2012, were computed by dividing the net result attributable to shareholders by the weighted average number of shares outstanding for the period (54,344 million at June 30, 2013).
Diluted earnings per share also amounted to 0.75 euros in the first half of 2013, compared with 0.84 euros in the same period in 2012, as the financial instruments outstanding that must be taken into account for dilution purposes did not have a material diluting effect.

Consolidated statement of financial position

(10) Property, plant and equipment

The table below shows the changes that occurred in this account as of June 30, 2013:

(in thousands of euros)	At December 31, 2012	Additions	Depreciation	Retirements	Translation adjustment	Reclassifications and other changes	At June 30, 2013
Land	2,323	-	-	-	2	-	2,325
Buildings	5,588	43	(397)	-	21	87	5,342
Plant and machinery	5,977	829	(548)	(1)	(104)	126	6,279
Manufacturing and distribution equipment	40,002	9,819	(8,976)	(1,640)	(416)	11	38,800
Other assets	6,466	737	(647)	(31)	(155)	-	6,370
Construction in progress and advances	4,960	743	-	(307)	(51)	(542)	4,803
Total property, plant and equipment	**65,316**	**12,171**	**(10,568)**	**(1,979)**	**(703)**	**(318)**	**63,919**

Additions to manufacturing and distribution equipment include purchases of medical equipment amounting to 9,027 thousand euros, down from 9,442 thousand euros at June 30, 2012. In the first six months of 2013, depreciation for the period totaled 7,391 thousand euros, compared with 6,798 in the same period in 2012.

(11) Goodwill and other intangibles

A breakdown of intangible assets at June 30, 2013 is as follows:

(in thousands of euros)	At December 31, 2012	Additions	Depreciation	Translation adjustment	Retirements and other changes	At June 30, 2013
Goodwill	67,689	-	-	(429)	(270)	66,990
Development costs	13,832	1,514	(929)	23	(11)	14,429
Concessions, licenses and trademarks	30,432	529	(1,505)	(508)	100	29,048
Industrial patents and intellectual property rights	13,100	70	(1,252)	(7)	230	12,141
Advances and other intangibles	223	46	(36)	(1)	(1)	231
Total intangible assets	**125,276**	**2,159**	**(3,722)**	**(922)**	**48**	**122,839**

Goodwill amounted to 66,990 thousand euros at June 30, 2013. The increase compared with December 31, 2012 also reflects the translation effect on the goodwill allocated to the Diasorin Brazil, Diasorin U.S.A. and Diasorin South Africa CGUs, for a negative amount equal to 429 thousand euros.
At June 30, 2013, the process of valuing the assets of Nordiag has been completed, with a reduction of 270 thousand euros in the purchase price accounted to reduce goodwill.

Please note that intangible assets with an indefinite useful life were not tested for impairment at June 30, 2013, since there were no indications of impairment. A full impairment test will be carried out in connection with the preparations of the annual financial statements.

(12) Equity investments

Equity investments, which totaled 513 thousand euros include 405 thousand euros for the investment held by the U.S subsidiary in the JV Diasorin Trivitron Healthcare Private Limited, 81 thousand euros for the investments held in Diasorin Switzerland AG, 26 thousand euros for the investment held by the German subsidiary in the U-Kasse pension fund and 1 thousand euros for the interest held in the Sobedia affiliated company.

This change occurred in the first half of 2013, equal to 336 thousand euros, is due to the investment in Diasorin Switzerland AG (since operating activities have not begun at June 30, 2013, the company has not been consolidated), the capital transfer in favor of Diasorin Trivitron Healthcare Private Limited subsidiary and the evaluation of investments in associates on the basis of the equity method

(13) Deferred-tax assets and deferred-tax liabilities

Deferred-tax assets amounted to 20,430 thousand euros. They relate to consolidated companies that have deferred-tax assets in excess of deferred-tax liabilities and to consolidation adjustments. Deferred-tax liabilities, which totaled 3,448 thousand euros, relate to consolidated companies that have deferred-tax liabilities in excess of deferred-tax assets. They are shown on the liabilities side of the statement of financial position.

The balance reflects the net deferred-tax assets computed on the consolidation adjustments (mainly from the elimination of unrealized gains on intra-Group transactions) and on temporary differences between the asset and liability amounts used to prepare the consolidated financial statements and the corresponding amounts used by the consolidated companies for tax purposes.

Deferred-tax assets were recognized in the financial statements when their future utilization was deemed probable. The same approach was used to recognize the benefit provided by the use of tax loss carry forwards, most of which, under current laws, can be brought forward indefinitely.

Based on the multi-year plans prepared by management, the Group is expected to generate sufficient taxable income in future years to allow for the full recovery of the abovementioned amounts.

An analysis of deferred-tax assets, net of offsettable deferred-tax liabilities, is provided below:

(In thousands of euros)	**6/30/2013**	**12/31/2012**
Deferred-tax assets	20,430	21,342
Deferred-tax liabilities	(3,448)	(3,579)
Total net deferred-tax assets	**16,982**	**17,763**

The Group offsets deferred-tax assets and liabilities when they refer to the same company. Depending on whether they are positive or negative, the resulting balances are recognized as deferred-tax assets or deferred-tax liabilities, respectively.

(14) Other non-current assets

The amount of 2,142 thousand euros, at June 30, 2013, refers mainly to receivables held by the Brazilian subsidiary.

(15) Inventories

A breakdown of inventories, at June, 2013, and compared with December 31, 2012, is provided below:

(in thousands of euros)	6/30/2013			12/31/2012		
	Gross amount	**Provisions for write-downs**	**Net amount**	**Gross amount**	**Provisions for write-downs**	**Net amount**
Raw materials and supplies	25,496	(1,990)	23,506	24,970	(2,006)	22,964
Work in progress	36,881	(2,778)	34,103	35,418	(2,770)	32,648
Finished goods	30,041	(1,617)	28,424	29,950	(1,590)	28,360
Total	**92,418**	**(6,385)**	**86,033**	**90,338**	**(6,366)**	**83,972**

The table below shows the changes that occurred in the provisions for inventory write-downs:

(in thousands of euros)	**6/30/2013**	**12/31/2012**
Opening balance	**6,366**	**6,521**
Additions for the period	813	755
Utilizations/reversals for the period	(744)	(826)
Current translation differences and other changes	(50)	(84)
Closing balance	**6,385**	**6,366**

The increase of 2,061 thousand euros in ending inventory, compared with December 31, 2012, is due to higher inventories of strategic materials at the Group's production facilities. These products are scheduled for launch in the coming months.

(16) Trade receivables

Trade receivables totaled 121,085 thousand euros at June 30, 2013. The table that follows shows the changes that occurred in the allowance for doubtful accounts, which amounted to 8,083 thousand euros at June 30, 2013:

(in thousands of euros)	**6/30/2013**	**12/31/2012**
Opening balance	**8,330**	**8,338**
Additions for the period	457	992
Utilizations/ reversals for the period	(546)	(725)
Currency translation differences and other changes	(158)	(275)
Closing Balance	**8,083**	**8,330**

In order to bridge the gap between contractual payment terms and actual collection dates, the Group assigns its receivables to factors without recourse. The receivables assigned by the Group's Parent Company in the first six months of 2013 totaled 22,744 thousand euros.

(17) Other current assets

Other current assets of 9,410 thousand euros (10,540 thousand euros at December 31, 2012) consist mainly of accrued income and prepaid expenses for insurance, interest, rentals and government grants, tax credits for foreign taxes withheld and advances paid to suppliers.

(18) Cash and cash equivalents

The components of cash and cash equivalents, which totaled 67,506 thousand euros (104,599 thousand euros at December 31, 2012), include regular bank and postal accounts and short-term bank deposits. Noteworthy is the dividend distribution, that amounted to 72,257 in the first half of 2013 (including 45,080 for the extraordinary dividend distribution in the early 2013) and the repayments of financing facilities amounting to 4,086 thousand euros.See the table in the pages above for further details.

(19) Shareholders' equity

Share capital

At June 30, 2013, the fully paid-in share capital consisted of 55,908 million common shares, par value of 1 euro each. It increased by 45 thousand euros, due to a capital increase carried out in connection with the 2007-2012 Stock Option Plan.

Additional paid-in capital

This account, which had a balance of 17,007 thousand euros, increased by 1,040 thousand euros, compared with December 31, 2012, due to a capital increase carried out in connection with the 2007-2012 Stock Option Plan.

Statutory reserve

This reserve amounted to 11,181 thousand euros at June 30, 2013. The appropriation of the 2012 net profit accounts for the increase compared with December 31, 2012

Other reserves

A breakdown of other reserves is as follows:

(in thousands of euros)	**6/30/2013**	**12/31/2012**	**Change**
Currency translation reserve	2,380	3,476	(1,096)
Reserve for treasury stock	44,882	44,882	-
Stock option reserve	3,805	3,336	469
OCI Reserve	(3,074)	(3,079)	5
Retained earnings	253,418	192,656	60,762
IFRS transition reserve	(2,973)	(2,973)	-
Consolidation reserve	904	904	-
Total other reserves and retained earnings	**299,342**	**239,202**	**60,140**
Including minority interest	***508***	***206***	***302***

Currency translation reserve

The decrease of 1,096 thousand euros shown in the currency translation reserve at June 30, 2013 is due to the fluctuation of the exchange rate of the Brazilian real and the South African rand. It also reflects the foreign exchange differences resulting from the translation at year-end exchange rates of the shareholders' equities of consolidated companies with financial statements denominated in foreign currencies, for a negative value equal to 1,254 thousand euros. This amount includes 429 thousand euros for adjustments to the goodwill allocated to CGUs that operate with currencies different from the euro.

This reserve also includes a gain of 158 thousand euros, net of tax effect (60 thousand euros), for translation differences on indebtedness denominated in foreign currencies held by the Group's Parent Company to hedge its investment in the shareholders' equity of the Diasorin USA subsidiary.

Reserve for treasury shares
With regard to treasury shares, the Company complied with all statutory requirements, purchasing treasury shares for amount covered by the distributable earnings and available reserves shown in its latest duly approved financial statements. Purchases were authorized by the Shareholders' Meeting and under no circumstance did the par value of the purchased shares exceed one-fifth of the share capital.
On January 17, 2011, the Company began to implement a program to buy treasury shares reserved for implementation of its new stock option plan, in accordance with the provisions and timing authorized by the Shareholders' Meeting on April 27, 2010. The program ended on February 15, 2011, with the purchase of 750,000 common shares, equal to 1.35% of the share capital, at an average price of 33.48 euros per share. A second program to buy treasury shares got under way on October 17, 2011, in accordance with the provisions and timing authorized by the Shareholders' Meeting of October 4, 2011.
Following these purchases, Diasorin S.p.A. holds a total of 1,550,000 treasury shares, equal to 2.77% of the share capital. The average purchase price of the 800,000 treasury shares purchased in the last quarter of the year was 24.71 euros per share. At June 30, 2013 the reserve for treasury shares amounted to 44,882 thousand euros. This reserve was established pursuant to law (Article 2357 *ter* of the Italian Civil Code) due to purchases of treasury shares made in 2011.

Stock option reserve
The balance in the stock option reserve refers to the 2007-2012 Stock Option Plan and the 2010 Stock Option Plan. In the first half of 2013, this reserve increased due to the recognition of stock option costs amounting to 737 thousand euros. The exercise of some tranches of the 2007-2012 Plan in the first half of 2013 caused a reduction of 268 thousand euros in the stock option reserve.

OCI reserve
OCI reserve is negative for 3,074 thousand euros and includes actuarial gains or losses resulting from the computation of the Group's defined-benefit pension plans, net of the applicable tax effect equal to 1,128 thousand euros

Retained earnings
The increase of 60,762 thousand euros in retained earnings, compared with December 31, 2012, is due mainly to the:

- appropriation of the consolidated net profit earned in 2012 (87,671 thousand euros);
- dividend distribution to the shareholders (27,177 thousand euros) approved on April 22, 2013 during the ordinary shareholders meeting (EUR 0.50 per share);
- The exercise of some tranches of the 2007-2012 Plan resulted in a positive change of 268 thousand euros in the stock option reserve.

IFRS transition reserve
The IFRS transition reserve was established on January 1, 2005, upon first-time adoption of the IFRSs as an offset to the adjustments recognized to make the financial statements prepared in accordance with Italian accounting principles consistent with IFRS requirements, net of the applicable tax effect (as required by and in accordance with IFRS 1). This reserve has not changed since it was first established.

Consolidation reserve
The consolidation reserve, amounting to 904 thousand euros, reflects the negative difference generated by the elimination of the carrying amounts of equity investments against the corresponding shareholders' equities.

(20) Borrowings and other financial liabilities/ (assets)

Borrowings include 529 thousand euros in long-term debt and 8,122 thousand euros for the current portion due within one year.

The table below lists the borrowings at June 30, 2013 (amounts in thousands of euros):

Lender	**Currency**	**Current portion**	**Non-current portion**	**Amount due after 5 years**	**Total**
GE Capital USD	$	8,540	-	-	8,540
	Amt. in EUR	6,529	-	-	6,529
GE Capital Euro	€	1,379	-	-	1,379
IMI MIUR	€	196	495	-	691
Finance leases	€	18	34	-	52
TOTAL		**8,122**	**529**	**-**	**8,651**

The table below lists the changes that occurred in the facilities outstanding as of the date of this semiannual report compared with December 31, 2012 (amounts in thousands of euros):

	Balance at 12/31/2012	**Repayments**	**Currency translation differences**	**Amortized cost effect**	**Balance at 6/30/2013**
GE Capital USD	9,707	(3,287)	85	24	6,529
GE Capital EUR	2,069	(690)	-	-	1,379
IMI MIUR	783	(107)	-	15	691
Finance leases	55	(2)	(1)	-	52
Total borrowings owed to financial institutions	**12,614**	**(4,086)**	**84**	**39**	**8,651**

The following amount was repaid in the first half of 2013: 4,300 thousand dollars to GE Capital (equal to 3,287 thousand euros), 690 thousand euros to GE Capital for the facility in euros, 107 thousand euros to IMI-Ministry of Education.

There were no changes in contract terms compared with December 31, 2012 and Diasorin was in compliance with all of the operating and financial covenants of the existing loan agreements.

Other financial liabilities, equal to 2,105 thousand euros at June 30, 2013 includes the measurement at fair value of financial instruments (negative value of 105 thousand euros at June 30, 2013 and a positive value of 263 thousand euros at December 31, 2012) and the Group's credit lines.

(21) Provision for employee severance indemnities and other employee benefits

The balance in this account reflects all of the Group's pension plans obligations, other post-employment benefits and benefits payable to employees when certain requirements are met. Group companies provide post-employment benefits to their employees by contributing to external funds and by funding defined-contribution and/or defined-benefit plans.
The manner in which these benefits are provided varies depending on the applicable statutory, tax-related and economic conditions in the countries where Group companies operate. As a rule, benefits are based on each employee's level of compensation and years of service. The Group's obligations refer to the employees currently on its payroll.

Defined-contribution plans

Certain Group companies pay contributions to private funds or insurance companies pursuant to a statutory or contractual obligation or on a voluntary basis. With the payment of these contributions, the companies in question absolve all of their obligations. The liability for contributions payable is included under other current liabilities. The cost attributable to each year, which accrues based on the services provided by employees, is recognized as a labor cost of the relevant organizational unit.

Defined-benefit plans

The Group's pension plans that qualify as defined-benefit plans include the provisions for employee severance indemnities in Italy, the Alecta system in Sweden and the U-Kasse pension plan and Direct Covenant system in Germany.

The liability owed under these plans is recognized at its actuarial value using the projected unit credit method. Any resulting actuarial gains or losses are recognized directly in equity.

Other employee benefits

The Group also provides its employees with additional long-term benefits, which are paid when employees reach a predetermined length of service. In these cases, the value of the liability recognized in the financial statements reflects the probability that these benefits will be paid and the length of time for which they will be paid. The liability owed under this plan is recognized at its actuarial value using the projected unit credit method. Any resulting actuarial gains or losses are recognized in the income statement.

The table that follows summarizes the Group's main employee benefit plans that are currently in effect:

(in thousands of euros)	**6/30/2013**	**12/31/2012**	**Change**
Employee benefits			
provided in:			
- Italy	6,498	6,352	146
- Germany	15,691	15,613	78
- Sweden	3,389	3,380	9
- Other	495	457	38
	26,073	**25,802**	**271**
Broken-down as follows			
- Defined-benefits plans			
Provision for employee severance indemnities	*5,242*	*5,167*	*75*
Other defined-benefit plans	*19,080*	*18,993*	*87*
	24,322	24,160	162
- Other long-term benefits	1,751	1,642	109
Total employee benefits	**26,073**	**25,802**	**271**

The table below shows the main changes that occurred in the first half of 2013:

(in thousands of euros)	**Defined-benefit plans**	**Other benefits**	**Total employee benefits**
Balance at December 31, 2012	**24,160**	**1,642**	**25,802**
Financial expense/(income)	414	4	418
Actuarial losses/(gains)	-	64	64
Actuarial losses/(gains) recognized directly in equity	(11)	-	(11)
Service costs	185	108	293
Contribution/benefits paid	(336)	(68)	(404)
Currency translation differences and other charges	(90)	1	(89)
Balance at June 30, 2013	**24,322**	**1,751**	**26,073**

(22) Other non-current liabilities

Other non-current liabilities, which totaled 3,409 thousand euros at June 30, 2013, consist mainly of provisions for risks and charges. The table that follows shows the changes that occurred in these provisions:

(in thousands of euros)	**6/30/2013**	**12/31/2012**
Opening balance	**3,417**	**4,165**
Addition for the period	58	190
Utilizations for the period	-	(27)
Reversals for the period	-	(793)
Currency translation differences and other charges	(66)	(118)
Ending balance	**3,409**	**3,417**

(23) Trade payables

Trade payables, which totaled 35,611 thousand euros at June 30, 2013, (37,206 at December 31, 2012) represent amounts owed to suppliers for purchases of goods and services. All amounts are due within the year.

(24) Other current liabilities

Other current liabilities of 24,630 thousand euros (24,572 at December 31, 2012) consist mainly of amounts owed to employees for statutory bonuses (17,109 thousand euros), contributions payable to social security and health benefit institutions (1,384 thousand euros).

(25) Taxes payable

The balance of 10,353 thousand euros (8,882 at December 31, 2012) represents the income tax liability for the profit earned in the first half of 2013, less estimated payments made, and amounts owed for other indirect taxes and fees.

(26) Commitments and contingent liabilities

Significant commitments and contractual obligations

Significant contractual obligations include the agreements executed by Diasorin S.p.A., the Group's Parent Company, and Stratec in connection with the development and production of the new chemiluminescent diagnostic system (LIAISON XL). The supply contract signed by Diasorin and Stratec calls for the latter to manufacture and supply exclusively to Diasorin the LIAISON XL analyzer. The Group has agreed to purchase a minimum number of systems. However, the projected commitment is deemed to be significantly lower than the normal level of capital investment that would be required for current or future equipment production. As a result, net invested capital is not expected to undergo significant structural changes in the future as a result of this commitment.

Contingent liabilities

The Diasorin Group operates globally. As a result, it is exposed to the risks that arise from the complex laws and regulations that apply to its commercial and manufacturing activities.
The Group believes that, overall, the amounts set aside for pending legal disputes in the corresponding provision for risks are adequate.

(27) Entries resulting from atypical and/or unusual transactions

As required by Consob Communication No. DEM/6064296 of July 28, 2006, the Company declares that, in the first half of 2013, the Group did not execute atypical and/or unusual transactions, as defined in the abovementioned Communication, according to which atypical and/or unusual transactions are transactions that, because of their significance/material amount, type of counterpart, subject of the transaction, method of determining the transfer price and timing of the event (proximity to the end of a reporting period), could create doubts with regard to: the fairness/completeness of the financial statement disclosures, the existence of a conflict of interest, the safety of the corporate assets and the protection of minority shareholders.

ANNEX I: THE COMPANIES OF THE DIASORIN GROUP AT JUNE 30, 2013

Company	Head office location	Currency	Share capital (*)	Par value per share or partnership interest	% interest held directly	Number of shares or partnership interests held
Companies consolidated line by line						
Diasorin S.A/N.V.	Bruxelles (Belgium)	**EUR**	1,674,000	6,696	99.99%	249
Diasorin Ltda	San Paolo (Brazil)	**BRL**	18,056,977	1	99.99%	18,056,976
Diasorin S.A.	Antony (France)	**EUR**	960,000	15	99.99%	62,492
Diasorin Iberia S.A.	Madrid (Spain)	**EUR**	1,453,687	6	99.99%	241,877
Diasorin Ltd	Oldbury (Great Britain)	**GBP**	500	1	100.00%	500
Diasorin Inc.	Stillwater (USA)	**USD**	1	0.01	100.00%	100
Diasorin Canada Inc	Mississauga (Canada)	**CAD**	200,000	N/A	-	100 Class A Common shares
Diasorin Mexico S.A de C.V.	Mexico City (Mexico)	**MXP**	63,768,473	1	99.99%	99,999
Diasorin Deutschland GmbH	Dietzenbach (Germany)	**EUR**	275,000	275,000	100.00%	1
Diasorin AB	Sundbyberg (Sweden)	**SEK**	5,000,000	100	100.00%	50,000
Diasorin Ltd	Rosh Haayin (Israel)	**ILS**	100	1	100.00%	100
Diasorin Austria GmbH	Vienna (Austria)	**EUR**	35,000	35,000	100.00%	1
Diasorin Czech s.r.o.	Prague (Czech Republic)	**CZK**	200,000	200,000	100.00%	1
Diasorin Diagnostics Ireland Limited	Dublin (Ireland)	**EUR**	3,923	0.01	100.00%	392,282
Diasorin Ireland Limited	Dublin (Ireland)	**EUR**	163,202	1.2	-	136,002
Biotrin Intellectual Properties Limited	Dublin (Ireland)	**EUR**	144	0.6	-	240
Diasorin I.N.UK Limited	Dublin (Ireland)	**EUR**	7,826,072	0.01	-	782,607,110
Diasorin South Africa (PTY) Ltd	Johannesburg (South Africa)	**ZAR**	101	1	100.00%	101
Diasorin Australia (Pty) Ltd	Sydney (Australia)	**AUD**	100	1	100.00%	100
Diasorin Ltd	Shanghai (China)	**RMB**	1,211,417	1	80.00%	96,000
Investments accounted for using the equity method						
Diasorin Trivitron Healthcare Private Limited	Chennai (India)	**INR**	42,000,000	10	-	2,142,000
Equity investments valued at cost						
Diasorin Switzerland AG	Zurich (Switzerland)	**CHF**	100,000	100	100.00%	1,000
Diasorin Deutschland Unterstuetzungskasse GmbH	Dietzenbach (Germany)	**EUR**	25,565	1	-	1
Consorzio Sobedia	Saluggia (Italy)	**EUR**	5,000	N/A	20.00%	1

(*) Amounts in local currencies.

CERTIFICATION OF THE CONDENSED SEMIANNUAL CONSOLIDATED FINANCIAL STATEMENTS PURSUANT TO ARTICLE 81-TER OF CONSOB REGULATION NO. 11971 OF MAY 14, 1999, AS AMENDED

We, the undersigned, Carlo Rosa, in my capacity as Chief Executive Officer, and Luigi De Angelis, in my capacity as Corporate Accounting Document Officer of Diasorin S.p.A,

attest that,

insofar as the provisions of Article 154-*bis*, Sections 3 and 4, of Legislative Decree No. 58 of February 24, 1998 are concerned, the administrative and accounting procedures applied during the first half of 2013 to prepare the condensed semiannual consolidated financial statement were:

a) adequate in light of the Company's characteristics; and

b) were applied effectively.

Moreover, we attest that the condensed semiannual consolidated financial statements:

a) were prepared in accordance with the applicable international accounting principles, as adopted by the European Union pursuant to Regulation (CE) No. 1606/2002 of the European Parliament and Council dated July 19, 2002;

b) correspond to the Company's books of accounts and bookkeeping entries;

c) are suitable for the purpose of providing a truthful and fair representation of the statement of financial position, operating performance and cash flow of the issuer and of the companies included in the scope of consolidation.

To the best of our knowledge, the interim Report on Operations provides a reliable analysis of significant events that occurred during the first half of the year and of their impact on the condensed semiannual financial statements, together with a description of the main risks and uncertainties for the remaining six months of the year.

The interim Report on Operations also provides a reliable analysis of information concerning transactions with related parties.

Saluggia, August 1, 2013

Signed:

Carlo Rosa — Chief Executive Officer

Luigi De Angelis — Corporate Accounting Document Officer